NZ763537B2 - Chewable formulation - Google Patents

Abstract

The present invention relates to a chewable formulation for delivering a nutritional or pharmaceutically active agent to an animal target. The chewable formulation comprises a nutritional ingredient or an effective amount of a pharmaceutically active agent, and a plasticiser. The chewable formulation is formed by extrusion and the formulation contains substantially no unbound water, nor is any water added in the manufacturing process. The present invention also relates to a method of manufacturing a shelf stable chewable formulation which comprises mixing the nutritional or pharmaceutically active agent with a fat, lipid or fat and lipid to obtain a first composition, adding one or more plasticizers to the first mixture to obtain a second composition, extruding the second composition at a temperature sufficient to melt the fat and lipid, and allowing the extruded second composition to cool to room temperature thereby providing the chewable formulation. n is formed by extrusion and the formulation contains substantially no unbound water, nor is any water added in the manufacturing process. The present invention also relates to a method of manufacturing a shelf stable chewable formulation which comprises mixing the nutritional or pharmaceutically active agent with a fat, lipid or fat and lipid to obtain a first composition, adding one or more plasticizers to the first mixture to obtain a second composition, extruding the second composition at a temperature sufficient to melt the fat and lipid, and allowing the extruded second composition to cool to room temperature thereby providing the chewable formulation.

Description

CHEWABLE VETERINARY FORMULATION FIELD OF THE INVENTION The present invention relates to a chewable formulation containing substantially no water in an unbound state. The present invention also relates to a method of manufacturing a chewable formulation by extrusion without the addition of water.

OUND TO THE INVENTION Chewable formulations are useful for the delivery of nutritional and pharmaceutically active ingredients. Such formulations are typically produced by extrusion.

Water is a vital ingredient in chewable treats manufactured by the extrusion process, as shown in the following patents.

US 2005/013714 uses natural meat flavouring, partially nized starch, softener and 9% water. NZ 580357 uses a nized onal protein matrix with 0.5- 40% water and water ty in range of 8.

NZ 580333 uses water or aqueous sorbitol used as ating fluid. US Patent 7,390,520 contains 8-18% water and 56-80% dry wheat . US 2005/013714 uses natural meat flavouring, partially gelatinized starch, softener and 9% water.

NZ 580357 uses a gelatinized functional protein matrix with 0.5-40% water and water activity in range of 0.6-0.8. NZ 580333 uses water or aqueous sorbitol used as granulating fluid. US Patent 7,390,520 contains 8-18% water and 56-80% dry wheat gluten.

High levels of water in chewable treat formulations can lead to a number of problems. Problems include, for example, microbial contamination and drying of the chew on storage. The presence of water may also cause the degradation of active ingredients, which may affect the stability, efficacy, and safety of the product during its shelf life.

Conversely, low levels of water may yield dry or crumbly products that may have poor texture in the mouth and may also be tible to egration during handling and shipping. Extrusion may also be difficult.

Chewable formulations must be palatable to the animal to which they intended to be red. However, providing a ation that is palatable and has acceptable shelf life can be challenging.

All documents cited or referenced herein ("herein cited documents"), and all documents cited or nced in herein cited documents, together with any manufacturer’s instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference , are hereby orated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

There is an ongoing need for new chewable formulations that avoid one or more of the disadvantages associated with existing chewable formulations; and/or to at least provide the public with a useful choice.

SUMMARY OF THE INVENTION In a first aspect, described is a shelf stable nary le formulation comprising a nutritional or pharmaceutically active agent, a plasticiser, and a lubricant selected from the group consisting of fats, , and a combination of fats and lipids, a filler, or a sweetener, or a filler and a sweetener, wherein the formulation is formed by extrusion and the formulation has a water activity (aw) of from about 0.1 to about 0.60.

In r aspect described is a method of manufacturing a shelf stable chewable veterinary ation comprising mixing a nutritional or pharmaceutically active agent with (1) a fat, lipid or fat and lipid, wherein the fat, lipid or fat and lipid is a lubricant, and (2) a filler, sweetener, or a filler and sweetener, to obtain a first composition, adding one or more plasticizers to the first mixture to obtain a second composition, and extruding the first composition or second composition under conditions effective to at least partially melt the fat, lipid, or fat and lipid, thereby providing the chewable formulation, and wherein the method of manufacture does not include the addition of water.

In another aspect described is a method of manufacturing a shelf stable chewable veterinary formulation sing mixing a nutritional or pharmaceutically active agent with a fat, lipid or fat and lipid to obtain a first composition, adding one or more cizers to the first mixture to obtain a second composition, extruding the second composition at a temperature sufficient to melt the fat and lipid, and allowing the extruded second composition to cool to room temperature thereby providing the chewable formulation, and wherein the method of manufacture does not include the addition of water.

Any one or more of the following embodiments may relate to any of the above s.

In one embodiment, the nutritional active agent is selected from a vitamin, a pro-vitamin, a mineral, a glycosaminoglycan or a nutritionally active monomer thereof, an amino acid, or a co-enzyme, or any combination of any two or more thereof.

In one embodiment, the pharmaceutically active agent is selected from anesthetics, corticosteroids, NSAIDS, antibiotics, antiemetics, hyroidal agents, parasiticidal agents, appetite stimulants, istamines, histamine rs, anti-fungal agents, otozoal , anti-depressants, or steroids, or any combination of any two or more thereof.

In one embodiment the pharmaceutically active agent is ed from anesthetics, corticosteroids, NSAIDS, antibiotics, antiemetics, anti-thyroidal agents or parasiticidal agents, or any combination of any two or more thereof.

In one embodiment, the pharmaceutically active agent selected from corticosteroids, NSAIDS, antiemetics, stamines, parasiticidal agents, or anthelmintics, or any combination of any two or more thereof.

In one embodiment, the pharmaceutically active agent is a parasiticidal agent.

In one embodiment the pharmaceutically active agent is an anthelmintic.

In one embodiment the pharmaceutically active agent is an NSAID.

In one ment, the pharmaceutically active agent is an antiemetic.

In one embodiment, the pharmaceutically active agent is an antihistamine.

In one embodiment, the pharmaceutically active agent is a corticosteroid.

In one embodiment the ional ingredient or pharmaceutically active agent is mixed by dry blending.

In an alternate embodiment the nutritional ingredient or pharmaceutically active agent may be dissolved in an appropriate solvent before addition.

In one embodiment, the nutritional ingredient or pharmaceutically active agent may be dissolved or suspended in a non-aqueous solvent before addition.

In one embodiment the nutritional ingredient or pharmaceutically active agent is granulated before mixing.

In one embodiment the nutritional ingredient or pharmaceutically active agent, optionally in granular form, are coated, or further coated, with a suitable coating.

In one embodiment the coating polymer is selected from polyethylene glycols, a wax, or a fatty acid.

In one embodiment the coating polymer is a saturated C18-C22 fatty acid.

More preferably the fatty acid is stearic acid.

In one embodiment the nutritional ingredient or an effective amount of a ceutically active agent (optionally in granular form) are ated with other substances, such as cyclodextrins, surfactants, or solubility or ilability ers, In one embodiment the water activity (aw) of the le formulation is less than 0.60, 0.59, 0.58, 0.57, 0.56, 0.55, 0.54, 0.53, 0.52, 0.51, 0.50, 0.49, 0.48, 0.47, 0.46, 0.45, 0.44, 0.43, 0.42, 0.41, 0.40, 0.38, 0.37, 0.36, 0.35, 0.34, 0.33, 0.32, 0.31, 0.30, 0.29, 0.28, 0.27, 0.26, 0.25, 0.24, 0.23, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11, 0.10, and useful ranges may be selected between any of these values.

In one embodiment the chewable formulation comprises  a filler, diluent or filler and t,  a binder,  a sweetener,  a flavouring agent,  a plasticizer,  a humectant,  a fat, lipid or fat and lipid,  an antioxidant,  a colouring agent,  a egrating agent, or  a preservative, buffering agent, or preservative and buffering agent, or  any ation of any two or more thereof.

In one embodiment the chewable formulation comprises  a filler, diluent or filler and diluent,  a binder,  a sweetener,  a flavouring agent,  a plasticizer,  a humectant,  a fat, lipid or fat and lipid,  an antioxidant,  a colouring agent,  a disintegrating agent,  a preservative, buffering agent, or preservative and buffering agent,  a lubricant,  a complexing agent,  a coating agent,  a surfactant,  a lity enhancer, ilability enhancer, or a solubility enhancer and a bioavailability enhancer,  a palatability enhancer, or  a non-aqueous solvent or vehicle, or  any combination of any two or more thereof.

In one embodiment the chewable formulation comprises one or more fillers.

In one embodiment a combination of s are used in the ation. In an alternate embodiment a ation of one or more fillers is used with one or more diluents. In an alternate embodiment a combination of diluents are used in the formulation.

In one embodiment the formulation comprises 2, 4, 6, 8, 10, 12, 14, 16, 18, , 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, or 90% by weight filler, diluent or filler and diluent, and useful ranges may be selected between any of these values.

In one embodiment the filler, diluent or filler and t are selected from starches and their derivatives (e.g. hydrogenated starch hydrosylate), celluloses and their derivatives (e.g. cellulose acetate), protein matrices (soy n, dextrates, wheat gluten, whey, corn cob, corn gluten), carbohydrates (e.g. maltodextrin, polydextrose), sugars and sugar alcohols (e.g. glucose, e, fructose, maltose, dextrose, sucrose, maltitol, xylitol, isomalt, mannitol), tes, calcium phosphates, calcium sulfate, dextrates, kaolin, magnesium carbonate, polymethacrylates, talc, or salts (e.g. sodium chloride) or any combination of any two or more thereof.

In one embodiment the formulation comprises about 15% by weight filler, diluent or filler and diluent.

In one embodiment the chewable formulation comprises one or more binders.

In one embodiment the formulation comprises 0.1, 0.2, 0.3, 0.5, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50% by weight binder, and useful ranges may be ed between any of these values.

In one embodiment, the ation comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, or 50% weight binder and/or filler, and useful ranges may be selected between any of these values.

In one embodiment the binder is selected from gums such as xanthan gum or guar gum, alginates, celluloses and their derivatives such as methylcellulose or microcrystalline cellulose, fats or lipids, starches and their derivatives, dextrins, celluloses and their derivatives, nes, silicates, mineral oils, vegetable oils, polymethacrylates, polyethylene oxides, gums, waxes, chitosan, rbophil, agar, or ers or any combination of any two or more thereof.

In one embodiment the binder is a gum such as guar gum or xanthan gum and is present in the formulation at about 0.2 to about 0.6, and more preferably 0.25 to about 0.5% by .

In one embodiment, the chewable formulation comprises one or more sweetners, flavouring , or palatability enhancers, or any combination of two or more thereof.

In one embodiment the chewable formulation comprises one or more sweeteners.

In one embodiment the formulation ses 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80% by weight ner, and useful ranges may be selected between any of these values.

In one embodiment the sweetener may be a natural ner such as glucose, fructose, sucrose (e.g. icing sugar), lactose, dextrose, glycerol, sorbitol, xylitol, maltitol, lactitol, glycerol, an artificial sweetener such as aspartame, a saccharin, acesulfame, sodium cyclamate, or any combination of any two or more thereof.

In one embodiment, the sweetener is selected from glucose, fructose, sucrose, e, dextrose, glycerol, ol, l, maltitol, lactitol, glycerol, aspartame, a saccharin, acesulfame, sodium cyclamate, steviol glycosides (stevia), rebaudiosides (e.g. ioside A), thaumatin, talin, sucralose, licorice and its derivatives, alitame, neotame, neohesperidin, or dihydrochalcone, or any combination of any two or more thereof.

In one embodiment, the chewable formulation comprises one or more flavouring agents, or palatability enhancers, or any combination of any two or more thereof.

In one embodiment the formulation comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25% by weight flavouring agent, or palatability enhancers, or any combination of any two or more thereof, and useful ranges may be ed between any of these values.

In one embodiment the chewable formulation comprises one or more ring agents.

In one embodiment the formulation comprises 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25% by weight flavouring agent, and useful ranges may be selected between any of these .

In one ment, the flavouring agent is an artificial flavouring agent, semi-synthetic flavouring agent, a natural flavouring agent, or nature identical ring agent.

In one embodiment, the flavouring agent is fruit, meat (e.g. pork, chicken, beef, fish), vegetable, dairy, honey, or plant derived, or is artificial.

In one ment, the flavouring agent is selected from beef flavour, artificial beef type flavour, beef mince, pork liver powder, cheese r, roast chicken hickory smoke, stewed beef, chicken fat, savoury flavouring, roast pork, fish flavouring, vanilla, creamy vanilla, butter caramel, peppermint, sweet apple, or any combination of any two or more thereof.

In one embodiment the flavouring agent is selected from artificial beef type flavour, beef mince, pork liver powder, cheese flavour, roast chicken hickory smoke, or any combination of any two or more f.

In one embodiment, the chewable formulation comprises one or more palatability enhancers.

In one embodiment, the chewable formulation comprises 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, , 21, 22, 23, 24 or 25% by weight palatability enhancer, and useful ranges may be selected between any of these .

In one embodiment, the palatability enhancer is a taste masking agent, a flavour potentiator, an aroma modifier, or a taste modifier, or any combination of any two or more thereof.

In one embodiment, the taste modifier is a bitter blocker.

In one embodiment, the bitter blocker is selected from polyethoxylated glycerol fatty acid , such as polyethylated castor oil (e.g. cremphor), extrins (e.g. β-cyclodextrin), flavanones (e.g. homoeriodictyol sodium salt), alkaline earth metal salts (e.g. zinc sulphate, magnesium sulphate), or celluloses and their derivatives (e.g. carboxymethylcellulose sodium salt), or any combination of any two or more thereof.

In one embodiment, the flavour potentiator is a sweetness enhancer.

In one embodiment, the sweetness enhancer is selected from pyridinium salts (e.g. alapyridaine), tuted benzoic acids (e.g. 2,4-dihydroxybenzoic acid), and positive eric modulators.

In one embodiment, the taste masking agent is selected from polyethoxylated glycerol fatty acid esters, such as hylated castor oil (e.g. hor), fats, or lipids, or any combination of any two or more thereof.

In one embodiment, the aroma modifier is selected from a r oil or flavour concentrate.

In one embodiment the chewable formulation ses 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45% by weight plasticizer, and useful ranges may be selected between any of these values.

In one embodiment the plasticizer may be selected from alcohols, glycols (such as propylene glycol), lanolin, wool fat, liquid paraffin, mineral oil, petrolatum, benzyl phenylformate, chlorobutanol, diethyl phthalate, glycerol, polyethylene glycol, propylene glycol, sorbitol, triacetin, benzyl phenyl formate, PLGA, rylates, phthalates, acetyltributyl citrate, acetyltriethyl citrate, castor oil, dibutyl sebacate, tributyl citrate, triethyl e, or any combination of any two or more thereof.

In one embodiment the chewable formulation comprises one or more humectants.

In one embodiment the chewable ation comprises 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90% by weight humectant, and useful ranges may be selected between any of these values.

In one ment the humectant is selected from sodium and potassium chloride, benzalkonium chloride, aluminium silicate, sodium propionates, sodium and potassium phosphates, sugars, sulfites, hydrogenated starch hydrosylate, etc. Liquid humectants include, but are not limited to, glycols, polyols, sugar alcohols, vegetable oils and mineral oil, hydrogenated vegetable oils, hydrocarbons, triacetin, liquid paraffin, or any combination of any two or more thereof.

In one embodiment the humectant is in a solid form.

In one embodiment the humectant is selected from propylene glycol and glycerine.

In one embodiment the chewable formulation comprises one or more lubricants.

In one embodiment the chewable formulation comprises 2, 3, 4, 5, 6 ,7 8, 9, , 11, 12, 13, 14, 15, 16, 17, 18% by weight lubricant, and useful ranges may be selected between any of these values.

In one ment, the lubricant is a fat, lipid or fat and lipid.

In one ment the fat, lipid, or fat and lipid is ed from shortening, tallow, stearates, glyceryl rate, glycerol monostearate, behenoyl polyoxy glyceride, hydrogenated coconut oil, hard fat, or any combination of any two or more thereof. Other fats/lipids known in the art may also be used.

In one embodiment the chewable formulation comprises an antioxidant.

In one embodiment the chewable ation comprises about 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5% by weight antioxidant, and useful ranges may be selected between any of these values.

In one embodiment the antioxidant is selected from propyl gallate, ascorbic acid and its derivatives, sodium formaldehyde sulfoxylate, malic acid, fumaric acid, editic acid, , enols, sodium EDTA, sodium ascorbate, sodium metabisulfite, butylated hydroxytoluene, butylated hydroxyanisole, or natural substances such as oids, tocopherols, carotenes, cysteine, or any combination of any two or more thereof. Other antioxidants known in the art may also be used.

In one embodiment, the chewable formulation comprises a non-aqueous solvent or vehicle.

In one embodiment, the non-aqueous solvent or vehicle is selected from glycerol formal, dimethyl sulfoxide, N-methylpyrrolidone, ethylene glycol, diethylene glycol hyl ether glycofurol, glycerol formal, acetone, alcohol, tetrahydrofurfuryl l, diglyme, dimethyl isosorbide, ethyl lactate.

In one embodiment, the chewable formulation comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25% by weight ueous solvent or vehicle, and useful ranges may be selected between any of these values.

In one embodiment the chewable formulation comprises a colouring agent.

In one embodiment the chewable formulation comprises a disintegrating agent.

In one embodiment the formulation comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30% by weight disintegrating agent, and useful ranges may be selected between any of these values.

In one embodiment the egrating agent is selected from povidones, croscarmellose sodium, sodium starch glycollate, oses and their tives, starches and their derivatives, gelatin, silicon dioxide, or any combination of any two or more f.

In one embodiment the chewable formulation comprises preservatives, buffering agents or preservatives and ing agents.

In one embodiment the chewable ation ses 2, 3, 4, 5, 6 , 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18% by weight fats, lipids or fats and lipids, and useful ranges may be selected between any of these values.

In one embodiment the preservative is selected from acids, alcohols, phenols, parabens, sorbates, thiols, phenylmercury salts, or any combination of any two or more thereof.

In one embodiment, the chewable formulation comprises a surfactant.

In one embodiment, the ation comprises about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20% surfactant by weight, and useful ranges may be selected n any of these values (for example, from about 2 to about 10% surfactant by weight).

In one embodiment, the surfactant is selected from propylene glycol esters (e.g. propylene glycol monocaprylate), PEGs, PEG esters, fatty acid glycerides (e.g. lauroyl ides), and anionic surfactants (e.g. sodium lauryl sulfate).

In one embodiment, the chewable formulation comprises a solubility enhancer, bioavailability enhancer, or a solubility enhancer and bioavailability enhancer.

The solubility enhancer and/or ilability enhancer enhances the solubility and/or bioavailability of the nutritional or pharmaceutically active agent.

In one embodiment, the chewable ation comprises about 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15% by weight solubility enhancer, bioavailability er, or solubility enhancer and bioavailability enhancer, and useful ranges may be ed between any of these values.

In one embodiment, the solubility er is ed from surfactants, complexing agents, buffers, or ionic salts, or any combination of any two or more thereof.

In one embodiment, the solubility enhancer is selected from sodium lauryl sulphate, polysorbates, spans, polyethylene glycols, bile salts, lecithin, phospholipids, poloxamers, polyoxyl 35 castor oil, medium chain mono- and diglycerides, propylene glycol monolaurate, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, tocopheyl polyethylene glycol succinate, polyoxylhydroxystearate, lauroyl polyoxyl-32 glycerides , nonionic triblock copolymers, polyoxyethylene (8) ic/capric glycerides, PEG-40 enated castor oil, diethylene glycol monoethyl ether and ocaproyl macrogol glycerides, or any combination of any two or more thereof. Any other suitable lity enhancers known in the art may be used.

In one embodiment, the bioavialbility enhancer is penetration enhancer.

In one embodiment, the bioavailability enhancer is a naturally or ly d bioavailability enhancer.

In one embodiment, the bioavailability enhancer is selected from quercetin, genistein, ol, naringin, sinomenine, piperine, glycyrrhizin, nitrile glycoside, cuminum cyminum, niaziridin, piperine, or allicine.

In one embodiment, the chewable formulation comprises one or more complexing agents.

In one embodiment, the nutritional or pharmaceutically active agent is complexed or conjugated with one or more complexing agents.

In one embodiment, the complexing agent is selected from EDTA, choleic acid, cyclodextrins (e.g. β-cyclodextrin), cyclic glucose oligomers, or polymers such as polethylene glycols, methyl cellulose, carboxy methyl cellulose and polyvinylpyrollidine, or any combination of any two or more thereof.

In one embodiment, the chewable formulation comprises about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70 or 80% complexing agent by weight, and useful ranges may be ed between any of these values (for example, from about 0.1% to about 30% complexing agent by weight). The amount used depends on the concentration of API and its affinity for the complexing agent.

In one embodiment, the molar ratio of API : complexing agent is about 4:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10, and useful ranges may be selected between any of these values (for example, from about 1:1 to about 1:10.

In one embodiment, the chewable formulation comprises one or more coating agents.

In one embodiment, the nutritional or pharmaceutically active agent, ally in granular form, are coated with the one or more coating agents.

In one embodiment, the chewable formulation comprises about 1% to about % coating agent by weight of the ional or pharmaceutically active agent.

In one embodiment, the coating agent is selected from polyethylene glycols, a wax, or a fatty acid, or a combination of any two or more thereof.

In one ment, the ation ses about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39% by weight liquid ingredients, and useful ranges may be selected n any of these values.

In one embodiment the chewable formulation is a single extrudate or coextrudate.

In one embodiment, the nutritional or pharmaceutically active agent is, prior to the addition of the plasticiser, combined with one or more ingredients selected from:  a filler, diluent or filler and diluent,  a binder,  a sweetener,  a flavouring agent,  a humectant,  a fat, lipid or fat and lipid,  an antioxidant,  a colouring agent,  a disintegrating agent,  a preservative, buffering agent, or preservative and buffering agent,  a lubricant,  a complexing agent,  a g agent,  a surfactant,  a solubility enhancer, bioavailability enhancer, or a solubility enhancer and a bioavailability enhancer,  a palatability enhancer, or  a non-aqueous solvent or vehicle, or  any combination of any two or more thereof.

In one embodiment, the one or more ingredients are in a dry state. In alternate embodiment, the one or more ingredients are not in liquid form.

In one embodiment, the nutritional or pharmaceutically active agent is combined with the one or more ingredient, prior to the on of the fat, lipid or fat and lipid.

In one embodiment, the fat, lipid or fat and lipid acts as a plasticiser and the first composition is extruded.

In one embodiment the active ient is, prior to the addition of the fat, lipid or fat and lipid, combined with  a filler,  a diluent,  a ner,  a flavouring agent,  a binder, or  a disintegrating agent, or  any combination of two or more of the above.

In one ment the filler, diluent, sweetener, flavouring agent, binder and disintegrating agent are all in a dry state.

In one embodiment the fat, lipid, or fat and lipid are pulverised before being added.

In one ment a plasticiser is added to the second composition.

In one ment, the plasticiser is in the form of a liquid.

In one embodiment, the extrusion is d out at a temperature and/or pressure sufficient to at least partially melt the fat, lipid, or fat and lipid.

In one embodiment, the ions are sufficient to melt at least 10, 15, 20, , 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95% of the fat, lipid, or fat and lipid.

In one embodiment, the conditions are effective to completely melt the fat, lipid, or fat and lipid.

In one embodiment, the method of manufacture is carried out without applying heat.

In one embodiment, the ion is carried out without applying heat.

In one embodiment the extrusion is performed under pressure ient to bind the ingredients together.

In one embodiment, the extruded composition is allowed to cool to room temperature after extrusion, thereby providing the chewable formulation.

In one embodiment, the le formulation is suitable for packaging immediately after extrusion.

In one embodiment, the method of manufacture further comprises packaging the chewable formulation.

In one embodiment, the chewable formulation is packaged immediately after extrusion.

In one embodiment, the chewable formulation is packaged within 1, 2, 3, 4, , 6, 7, 8, 9, 10, 15, 30, 60, 90, or 120 minutes after extrusion, and useful ranges may be selected n any of these values.

In another embodiment, the chewable formulation is packaged within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, 24, 48, or 72 hours extrusion, and useful ranges may be selected n any of these values.

In one embodiment, the extruded composition is not allowed to cool or cooled prior to packaging.

In one embodiment, the extruded ition is not cured prior to packaging.

In one embodiment, the packaging is hermetic.

In one embodiment, the chewable formulation is formed on extrusion.

In one embodiment, the chewable formulation is packaged without cooling or curing.

In one embodiment, the method of manufacturing the shelf stable chewable formulation is continuous.

In one ment, the method of manufacture comprises co-extruding at least one additional composition.

In one embodiment, the at least one additional ition comprises a processed or unprocessed food al, or a nutritional or pharmaceutically active agent, or any combination of any two or more thereof.

In one embodiment, the food material is of plant or animal origin. In one embodiment, the food material is confectionary.

In one embodiment, the at least one additional composition comprises a palatable chewable base and optionally a nutritional or pharmaceutically active agent.

In one embodiment, the first or second ition comprises an unpalatable ional or pharmaceutically active agent and the at least one additional composition comprises a palatable chewable base and optionally a nutritional or pharmaceutically active agent.

In one embodiment, the at least one onal composition comprises  a filler, t or filler and diluent,  a binder,  a sweetener,  a flavouring agent,  a plasticizer,  a humectant,  a fat, lipid or fat and lipid,  an antioxidant,  a colouring agent,  a disintegrating agent,  a preservative, buffering agent, or preservative and ing agent,  a lubricant,  a complexing agent,  a coating agent,  a surfactant,  a solubility enhancer, bioavailability enhancer, or a solubility er and a bioavailability enhancer,  a palatability enhancer, or  a non-aqueous solvent or vehicle, or  any combination of any two or more thereof.

In one embodiment at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% by weight of any water present in the chewable formulation is present in a bound state, and useful ranges may be selected n any of these .

In one embodiment the chewable formulations may have acceptable physical and chemical stability, providing at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 months shelf life, and useful ranges may be selected between any of these values.

In one embodiment, the chewable formulation is chewable for at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 months.

In one embodiment, the chewable formulation has a chewiness of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, .9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 N, and useful ranges may be selected between any of these values.

In one embodiment, the chewable formulation has a hardness of about 1000, 950, 900, 850, 800, 750, 725, 700, 675, 650, 625, 600, 575, 550, 525, 500, 475, 450, 425, 400, 375, 350, 325, 300, 275, 250, 225, 200, 175, 150, 125, 100, 75, 50, 25, 20, , or 10 N, and useful ranges may be ed between any of these values.

In one embodiment, the chewable formulation has a compression energy of energy of about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, or 3000 N.mm, and useful ranges may be selected between any of these values.

In one embodiment, the chewable formulation has an adhesion of about 0, - 0.5, -1, -1.5, -2, -2.5, -3, -3.5, -4, -4.5, -5, -5.5, -6, -6.5, -7, -7.5, -8, -8.5, -9, -9.5, - , -11, -12, -13, -14, -15, -16, -17, -18, -19, or -20 N.mm, and useful ranges may be ed between any of these values.

In one embodiment, the chewable formulation has a cohesiveness of about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, or 0.5, and useful ranges may be ed between any of these values.

In one ment, the chewable formulation has a springiness of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40%, and useful ranges may be selected between any of these values.

In one embodiment, the chewable formulation has a modulus of about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 N/mm, and useful ranges may be selected between any of these values.

In one ment the chewable formulation delivers at least 80% of the active ingredient g within 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90 or 95 minutes, and useful ranges may be selected between any of these In one embodiment, the chewable formulation provides sustained ry of the nutritional or pharmaceutically active ingredient over an extended period of time. In one embodiment, the active ingredient is delivered over 2, 4, 6, 8, 10, 12, 24, 48, 60, 72, 96, 120, 144, or 168 hours, and useful ranges may be selected between any of these values.

In one embodiment, the chewable formulation provides delayed delivery of the nutritional or pharmaceutically active ingredient. In one embodiment, delivery is delayed by about 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, or 72 hours, and useful ranges may be selected between any of these values.

In one embodiment the chewable formulation substantially retains its malleability throughout the shelf-stable .

In one embodiment, the chewable formulation substantially retains a characteristic ed from chewiness, hardness, compression energy, adhesion, veness, springiness, modulus, and any combination of any two or more thereof (as measured by the method described in Example 7).

In one embodiment the le ation does not dry out nor become brittle over the shelf-stable period.

In one embodiment, the release characteristics of the nutritional or pharmaceutically active agent are ntially maintained throughout the shelf-stable period.

In one ment, the chewable formulation rs the nutritional or pharmaceutically active agent at substantially the same dose and rate throughout the shelf stable .

In another aspect the invention the invention is the use of any one or more of the compositions described above.

In another aspect the invention the invention may be the use of any one or more of the compositions described above.

In another aspect, the invention relates to the use of a chewable formulation of the invention for ng an animal in need thereof.

In another aspect, the invention relates to a method of treating an animal in need thereof with a chewable formulation of the invention.

In another aspect, the invention relates to use of a nutritional or pharmaceutically active agent, and a plasticiser in the manufacture of a chewable formulation of the invention for treating an animal in need thereof.

In another aspect, the invention relates to a shelf stable chewable formulation manufactured by a method of the invention.

It is intended that reference to a range of numbers disclosed herein (for example, 1 to 10) also incorporates reference to all rational numbers within that range (for example, 1, 1.1, 2, 3, 3.9, 4, 5, 6, 6.5, 7, 8, 9 and 10) and also any range of rational numbers within that range (for example, 2 to 8, 1.5 to 5.5 and 3.1 to 4.7).

As used herein, the term "substantially" means at least 90, 95 or 99%.

To those skilled in the art to which the invention relates, many changes in construction and widely ing embodiments and applications of the invention will suggest themselves without departing from the scope of the invention as defined in the appended claims. The disclosures and the descriptions herein are purely illustrative and are not ed to be in any sense ng In this specification, where reference has been made to al sources of information, including patent specifications and other documents, this is lly for the e of providing a context for sing the features of the present invention.

Unless stated otherwise, reference to such sources of information is not to be construed, in any jurisdiction, as an admission that such sources of information are prior art or form part of the common general knowledge in the art.

Accordingly, it is an object of the invention to not encompass within the invention any previously known product, process of making the product, or method of using the product such that Applicants reserve the right and hereby disclose a disclaimer of any previously known product, process, or method. It is further noted that the invention does not intend to encompass within the scope of the invention any product, process, or making of the product or method of using the product, which does not meet the n description and enablement requirements of the USPTO (35 U.S.C. §112, first paragraph) or the EPO le 83 of the EPC), such that Applicants reserve the right and hereby disclose a disclaimer of any previously described t, process of making the product, or method of using the product.

It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as "comprises", "comprised", "comprising" and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting essentially of" and "consists ially of" have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.

These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description.

BRIEF DESCRIPTION OF THE GS The following detailed description, given by way of example, but not ed to limit the ion solely to the specific ments described, may best be tood in conjunction with the accompanying drawings.

Figure 1 depicts a representative schematic of the invention.

Figure 2 shows a double compression curve for a placebo chewable formulation. The curve is a plot of force (N) d to a cylindrical ate of the chewable formulation over time.

Figure 3 shows the dissolution profiles of eight chewable formulations.

DETAILED DESCRIPTION OF THE INVENTION The t ion relates to the preparation of a chewable treat manufactured by extrusion and which does not n water in a free state. Without wishing to be limited by theory, the absence of water in a free state  reduces the risk of microbial contamination,  improves chemical stability of the nutritional and pharmaceutical ingredients,  prevents the dosage unit from becoming hard and brittle over time, or  any combination of two or more of the above.

The present invention provides a simple and effective method for preparing of semi-soft, palatable and stable chewable treat without addition of water.

It should be appreciated that the present invention provides a platform for administering therapeutic ingredients and/or nutritional ingredients to veterinary animals.

The present invention also relates to a composition for the manufacture of stable and palatable, fast disintegrating, semi-soft medicated chewable tablets (treats) by extrusion t the addition of extraneous water. The soft chewable tablets do not harden on storage and are resistant to microbial contamination.

In one embodiment the semi-soft chewable treats contain a blend of any one or more of binders, flavours, palatability enhancers, humectants, disintegrating agents, non-aqueous solvents, and diluents that are plasticized with liquid plasticizers, such as glycols and polyols to make them ductile and extrudable.

The present invention provides an extrudable chew that  uses fats or lipids as plasticizers and binding agents,  is manufactured in the absence of added water,  uses plasticizers to replace water in extrudable matrices,  contains humectants to maintain the able chew in a pliant and soft state during its shelf life, or  any combination of two or more of the above.

The components of the invention are described as follows.

The chewable composition of the present invention is a platform technology to allow delivery of an active ingredient in a le form to an animal. A wide range of active ingredients can be delivered orally by the chewable platform formulation of the t invention. The active ingredient may be any orally active drug or other biologically active nd known in art for human and/or veterinary pharmaceuticals and nutraceuticals.

For example, the active ingredient may be a ional ingredient. A nutritional supplement includes any ingredient whose purpose is to assist or in the health of the target animal. For e, the nutritional supplement may provide a nutritional benefit to the target animal.

In some embodiments the chewable formulation delivers a therapeutic substance to the target animal, such as a pharmaceutically active agent.

The pharmaceutically active agent can be chosen from various treatment groups, such as anesthetics, corticosteroids, NSAIDS, antibiotics, antiemetics, antithyroidal agents or parasiticidal agents; or they could be selected for their nutritional value such as for example, vitamins or minerals or a combination thereof.

As a non-limiting example, the nutritional active could be a vitamin. iting es of vitamins e vitamin A, vitamin E, vitamin B12, vitamin B3, dpantothenic acid (vitamin B5), folic acid, vitamin B6, vitamin B1, vitamin D3, vitamin C, vitamin B2. As another example, the nutritional active could be a tamin, for example beta-carotene or panthenol.

As another non-limiting example, the nutritional active could be a mineral.

Non-limiting examples of minerals include ium, sodium, manganese, zinc, iron, calcium, copper, cobalt, iodine, chlorine and selenium. The mineral may be in the form of a suitable salt.

As another example, the nutritional active could be a glycosaminoglycan or a nutritionally active monomer thereof. As a non-limiting example, the glycosaminoglycan could be chondroitin. As a non-limiting example, the glycosaminoglycan monomer could be glucosamine.

As another e, the nutritional active could be an amino acid. Suitable amino acids include but are not limited to the 20 naturally ing L-amino acids, for example arginine, isoleucine, e, , etc.

As another example, the nutritional active could be a co-enzyme, for example co-enzyme Q. n, pro-vitamin, mineral, glycosaminoglycan or a nutritionally active monomer thereof, an amino acid, or a co-enzyme.

As a non-limiting example, the pharmaceutically active agent could be a NSAID such as meloxicam or carprofen. As another non-limiting example the pharmaceutically active agent could be selected from an anthelmintic such as a macrocyclic lactone, benzimidazole, imidazothiazole or salicylanilide. As an example of a macrocyclic lactone the pharmaceutically active agent could be selected from abamectin, moxidectin, avermectin, ivermectin, selamectin or cydectin. As an example of a benzimidazole, the pharmaceutically active agent could be selected from mebendazole, fenbendazole, oxfendazole, azole, thiabendazole or carbendazol. As an e of an othiazole, the pharmaceutically active agent could be selected from levamisole, pyrantel pamoate, butamisole, or tetramisole. As an example of a salicylanilide the pharmaceutically active agent could be selected from clioxanide, closantel or niclosamide.

In one embodiment, the pharmaceutically active agent is an anesthetic.

Anesthetics include, but are not limited to, local anesthetics, such as procaine, bupivicaine, lidocaine and proparacaine, phenothiazine and buterophenone sedatives, for example acepromazine, chlorpromazine, droperidol and azaperone, benzodiazapines, such as diazepam, lam and zolazepam, alpha-2 adrenergic agonists, such as thiazines, for example xylazine, and medetomidine, s, for example orphine, pentazocine, hine, butorphanol, fentanyl, morphine, meperidine, and oxymorphone, urates, such as phenobarbital, thiopental, and thiamylal, and dissociative anesthetics, such as ketamine and tiletamine.

In one embodiment, the pharmaceutically active agent is an analgesic. sics include, but are not limited to, opioid analgesics and non-opioid analgesics, for e non-steroidal anti-inflammatories, such as those described herein. Non-limiting es of opioid analgesics e buprenorphine, butorphanol, dextromoramide, dezocine, dextropropoxyphene, diamorphine, fentanyl, alfentanil, anil, hydrocodone, hydromorphone, midone, levomethadyl acetate, mepiridine, methadone, morphine, nalbuphine, opium, oxycodone, papaveretum, pentazocine, pethidine, phenoperidine, piritramide, dextropropoxyphene, remifentanil, tilidine, tramadol, codeine, dihydrocodeine, meptazinol, dezocine, eptazocine and flupirtine.

In one ment, the pharmaceutically active agent is a corticosteroid.

Non-limiting examples of corticosteroids include endogenous and synthetic adrenocorticoid steroids. These include, but are not limited to, hydrocortisone, betamethasone, cortisone, dexamethasone, solone, prednisone, methylprednisilone, triamcinolone, flumethasone, and their pharmaceutically acceptable derivitives.

In one embodiment, the pharmaceutically active agent is an NSAID. NSAIDs include, but are not d to, carboxylic acid and enolic acid derivatives. Enolic acid NSAIDs include, but are not limited to, pyrazolones (e.g. phenylbutazone, nbutazone, and nazone) and oxicams (e.g. meloxicam, cam, and tenoxicam). Carboxylic acid NSAIDs include, but are not limited to, salicylates (e.g. aspirin), propionic acids (e.g. ibuprofen, naproxen, carprofen, ketoprofen, and vedaprofen), anthranilic acids (e.g. tolfenamic and enamic acids), acetic acids (e.g. acetaminophen), aminonicotinic acids (e.g. flunixin), and indolines (e.g. thacin).

Further non-limiting examples of NSAIDs include acemetacin, acetylsalicylic acid (aspirin), alminoprofen, benoxaprofen, bucloxic acid, carprofen, celecoxib, clidanac, deracoxib, diclofenac, diflunisal, dipyrone, etodolac, fenoprofen, zac, firocoxib, flobufen, flufenamic acid, flufenisal, flunixin, fluprofen, flurbiprofen, ibuprofen, indomethacin, indoprofen, isoxicam, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, meloxicam, miroprofen, nabumetone, naproxen, niflumic acid, oxaprozin, oxepinac, phenylbutazone, piroxicam, pirprofen, pramoprofen, sudoxicam, sulindac, suprofen, tepoxalin, tiaprofenic acid, tiopinac, tolfenamic acid, tolmetin, trioxaprofen, zidometacin, or zomepirac, pharmaceutically acceptable salts thereof and mixtures thereof.

In one embodiment, the pharmaceutically active agent is an antibiotic. Nonlimiting examples of antibiotics include beta-lactams such as penicillins, aminopenicillins (e.g., amoxicillin, ampicillin, hetacillin), llinase resistant antibiotics (e.g., cloxacillin, dicloxacillin, methicillin, nafcillin, oxacillin), extended spectrum antibiotics (e.g., axlocillin, carbenicillin, mezlocillin, piperacillin, ticarcillin); cephalosporins (e.g., cefadroxil, cefazolin, cephalixin, cephalothin, cephapirin, cephradine, cefaclor, cefacmandole, cefmetazole, cefonicid, ceforanide, cefotetan, cefoxitin, cefprozil, xime, loracarbef, me, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftiofur, ceftizoxime, ceftriaxone, ctam); monobactams such as nam; carbapenems such as imipenem and eropenem; quinolones (e.g., ciprofloxacin, enrofloxacin, difloxacin, orbifloxacin, marbofloxacin); chloramphenicols (e.g., chloramphenicol, thiamphenicol, florfenicol); yclines (e.g., chlortetracycline, tetracycline, oxytetracycline, doxycycline, minocycline); macrolides (e.g., erythromycin, tylosin, tlimicosin, hromycin, azithromycin); lincosamides (e.g., lincomycin, clindamycin); aminoglycosides (e.g., gentamicin, amikacin, kanamycin, apramycin, tobramycin, neomycin, dihydrostreptomycin, mycin); amides (e.g., sulfadmethoxine, sfulfamethazine, sulfaquinoxaline, sulfamerazine, sulfathiazole, sulfasalazine, sulfadiazine, sulfabromomethazine, suflaethoxypyridazine); glycopeptides (e.g., vancomycin, teicoplanin, ramoplanin, and decaplanin); and other antibiotics (e.g., rifampin, nitrofuran, virginiamycin, polymyxins, tobramycin).

In one embodiment, the pharmaceutically active agent is an antiemetic. miting examples of antiemetics e phenothiazines (e.g. prochloperazine, promethazine, thiethylperazine, perphenazine, chlorpromazine, metopimazine, mazine), 5HT-3 or antagonists such as ondansetron, granisetron, tropisetron, dolasetron, hydrodolasetron, azasetron, ramosetron, lerisetron, indisetron and palonosetron, and others such as ydrinate, diphenhydramine (which can also act as an antihistamine), cyclizine, meclizine, hazine, hyroxyzine, metoclopramide, domperidone, hyoscine, hyoscine hydrobromide, hyoscine hydrochloride, amine, clebopride, alizapride, itopride, bromopride, droperidol, haloperidol, benzquinamide, cerium oxalate, idol, dronabinol, nabilone, ginger, levosulpiride, butorphanol and aprepitant.

In one embodiment, the pharmaceutically active agent is an anti-thyroidal agent. Anti-thyroidal agents include, but are not d to, carbimazole, methimazole, and propylthiouracil.

In one embodiment, the pharmaceutically active agent is a parasiticidal agent. miting examples of parasiticidal agents include macrocyclic lactones such as abamectin, ivermectin, eprinomectin, doramectin, ctin, selamectin, milbemycin oxime.

The ticidal agent may be an endoparasiticidal agent, ectoparaciticidal agent, orendectoparaciticidal agent. Ectoparasiticides include, for e, organochlorines, organophosphates, carbamates, amidines, pyrethrins and synthetic pyrethroids, benzoylureas, juvenile hormone analogues, macrocyclic lactones, neonicotinoids, phenylpyrazoles, and spinosyns, such as ad. Endectoparaciticides include, for e, macrocyclic lactones, such as ivermectin. Endoparasiticides include, for example, anthelmintics, such as those described herein. Examples of parasiticidal agents include avermectin, milbemycin, pyrazole, nodulisporic acid, clorsulon, closantel, rine, quine, vidarabine, nitenpyram, ivermectin, milbemycine oxime, lufenuron, salimectin, moxidectin, dorimectin, and paraherquamide.

In one embodiment, the pharmaceutically active agent is an anthelmintic.

Anthelmintics include, but are not limited to, benzimidazoles, imidazothiazoles, tetrahydropyrimidines, macrocyclic lactones, salicylanilides, substituted phenols, aromatic amides, nolines, amino acetonitriles, ndoles.

Anthelmintic benzimidazoles include, but are not limited to, mebendazole, flubendazole, fenbendazole, oxfendazole, oxibendazole, albendazole, albendazole sulfoxide, thiabendazole, thiophanate, febantel, netobimin, and triclabendazole. Further examples include mebendazole, and ricobendazole.

Imidazothiazoles and tetrahydropyrimidines are both nicotinic agonists.

Anthelmintic imidathiazoles include, but are not limited to, levamisole, tetramisole, and butamisole. ydropyrimidine anthelmintics include, for example, morantel, oxantel, and pyrantel.

Macrocyclic lactones include, but are not limited to, abamectins, for example abamectin, doramectin, eprinomectin, ivermectin, and selamectin, and milbemycins, for example milbemycin oxime and moxidectin.

Salicylanilides include, but are not limited to, brotianide, clioxanide, closantel, niclosamide, oxyclozanide, and rafoxanide. tuted phenols include, but are not d to, nol, disophenol, hexachlorophene, niclofolan, menichlopholan, and nitroxynil. Aromatic amides include diamfenetide.

Isoquinoline anthelmintics include, but are not d to, praziquantel and epsiprantel. Amino-acetonitrile derivatives include, but are not limited to, monepantel.

Further examples of mintics include, but are not limited to, piperazine and derivatives thereof such as piperazine and diethylcarbamazine, benzenesulfonamides such as clorsulon, amidines such as bunamidine, isothiocyantes such as nitroscanate, and organophosphates such as dichlorvos, and spiroindoles such as derquantel.

In one embodiment, the pharmaceutically active agent is an appetite stimulant. There are several widely used drugs which can cause a boost in appetite.

Examples, include, but are not limited to, tricyclic antidepressants , tetracyclic antidepressants, natural or synthetic inoids, first-generation antihistamines, antipsychotics, steroid hormones, and ghrelin receptor agonists such as orelin.

Non-limiting examples of appetite stimulants used in pets include cyproheptadine, diazepam, mirtazapine, megesterol acetate, stanozolol. Examples of te stimulants used in humans e medroxyprogesterone acetate, dronabinole, and dexamethasone.

In one ment, the pharmaceutically active agent is an istamine.

Non-limiting examples of antihistamines include cetirizine, clemastine, clemastine fumarate, dexmedetomidine, doxylamine, loratidine, desloratidine and promethazine, and diphenhydramine, or pharmaceutically acceptable salts, solvates or esters thereof.

In one embodiment, the pharmaceutically active agent is a histamine blocker. Histamine rs include but are not limited to cimetidine, famotidine, nizatidine, and ranitidine.

In one embodiment, the pharmaceutically active agent is an anti-fungal agent. Anti-fungals include but are not d to polyenes, azoles, allylamines, morpholines, antimetabolites, and combinations thereof. Non-limiting examples include nystatin, fluconazole, itraconazole, clotrimazole, ketoconazole, terbinafine, 5- cytosine, and amphotericin B.

In one embodiment, the pharmaceutically active agent is an antiprotozoal agent. Non-limiting examples of antiprotozoal agents e eflornithine, furazolidone, melarsoprol, metronidazole, ornidazole, mycin te, pentamidine, pyrimethamine and tinidazole. Antiprotozoal agents include coccidostats. Examples of coccidostats include, but are not limited to, amprolium, arprinocid, artemether, clopidol, decoquinate, diclazuril, lmide, ethopabate, halofuginone, lasalocid, monensin, narasin, nicarbazin, oryzalin, robenidine, roxarsone, salinomycin, spiramycin, sulfadiazine, and toltrazuril.

In one embodiment, the pharmaceutically active agent is an anti-depressant.

Anti-depressants include but are not limited to serotonin reuptake inhibitors and tricyclic antidepressants, for example amitriptyline and clomipramine.

In one embodiment, the the ceutically active agent is a steroid. ds include, for example, corticosteroids such as those described herein. Further non-limiting examples e paramethasone, betamethasone, dexamethasone, fludrocortisone, stanozolol, one clenate, and trenbolone acetate.

Steroids include l and synthetic steroid hormones, steroid hormone sors, steroid hormone metabolites, and derivatives thereof structurally derived from cholesterol. Steroid hormones include, but are not limited to, androgens, estrogens, progestogens, mineralcorticoids, and glucocorticoids. Non-limiting examples of ens include testosterone, dehydroepiandrosterone, oepiandrosterone sulphate, dihydrotestosterone, androstenedione, tenediol, tanedione, and androstanediol. Non-limiting examples of estrogens include estrone, estradiol, estriol, estetrol, equilin, and equilenin. Non-limiting examples of progestogens e progesterone, 17-hydroxy- progesterone, pregnenolone, dihydroprogesterone, allopregnanolone, 17-hydroxy- pregnenolone, 17-hydroxy-dihydroprogesterone, and 17- y-allopregnanolone. Non-limiting examples of mineralcorticoids include aldosterone, 11- deoxycorticosterone, fludrocortisones, 1 1-deoxy-cortisol, and pregnenedione. Non-limiting examples of glucocorticoids include cortisol (hydrocortisone), corticosterone, 18-hydroxy-corticosterone, cortisone.

In one embodiment the nutritional ient or pharmaceutically active agent is added to the composition by dry blending.

In one embodiment the nutritional ingredient or pharmaceutically active agent may be dissolved in an appropriate solvent before addition to the composition.

In one embodiment, the nutritional ingredient or pharmaceutically active agent may be dissolved, emulsified, or suspended in a non-aqueous solvent before addition.

In one embodiment the nutritional ingredient or pharmaceutically active agent is granulated before addition to the composition to improve distribution and/or improve chemical stability. In one embodiment, granulation masks offensive tastes and/or offensive odours.

In one embodiment the nutritional ingredient or ceutically active agent, optionally in granular form, are coated, or further coated, with a suitable coating.

In one embodiment the coating is a coating polymer that coats and protects the nutritional ingredient or pharmaceutically active agent. In another embodiment, the coating masks offensive taste and/or offensive odour. In one embodiment the coating polymer is selected from polyethylene glycols, a wax, or a fatty acid.

In one embodiment the g r is a wax is sourced from animal, vegetable, l, eum or synthetic waxes. More preferably, the wax is an animal wax such as x.

In an alternate embodiment the coating polymer is a saturated C18-C22 fatty acid. More preferably the fatty acid is stearic acid.

The nutritional or pharmaceutically active agent may be e, partially soluble, or insoluble in water.

In one embodiment the nutritional ingredient or pharmaceutically active agent (optionally in ar form) are conjugated with other substances, such as cyclodextrins, surfactants, solubility or bioavailability enhancers, etc., to inhibit ctions with other excipients or with the environment, promote its chemical stability, improve solubility, enhance ilability, or improve ility. Similarly, the pharmaceutically active agent may be incorporated in to novel drug delivery systems, such as microcapsules, liposomes, niosomes, nanoparticles, mulsions, or nanoemulsions to protect the drug or permit organ targeting.

In one embodiment, the chewable formulation comprises two or more nutritional or pharmaceutically active agents.

In one embodiment the chewable formulation comprises a nutritional ingredient and pharmaceutically active agent.

In some embodiments the composition includes the presence of one or more excipients.

In some embodiments a single excipient has more than one function in the formulation of the present invention. For e, propylene glycol and glycerol may be present and have a simultaneous role as a plasticizer, humectant, antimicrobial agents, or any combination of any two or more thereof, in this formulation. Sugar may have a role as a sweetener, humectant, diluent, or any combination of any two or more thereof.

Lipids or fats may have a role as a lubricant, plasticizer, binders, or any ation of any two or more thereof. Any suitable excipient may be used.

Table 1 below describes preferred ingredients as well as examples and/or alternatives that could be used in the present ion.

Table 1. List of ients used the chewable formulation of the present invention.

Ingredient Function Examples and/or alternatives (can be used alone or in combination) Ascorbyl Palmitate Antioxidant Propyl gallate, ascorbic acid, sodium ascorbate, sodium metabisulfite, thiols, polyphenols, BHT, -Tocopherol Antioxidant c acid, malic acid, Editic acid (EDTA), flavonoids Cellulose powder Filler nt Cellulose derivatives, starch derivatives, calcium phosphates, cellulose acetate, dextrates, starches and derivatives, silicates, protein powders, wheat gluten, soy powder, sugars and sugar ls Microcrystalline Dry Binder Povidones, starches, oses, silicates, cellulose + Ca2PO4 alginates, gums, waxes Methylcellulose Dry Binder Povidones, starches, celluloses, silicates, alginates, gums, waxes Beef Type Flavour Flavouring Any artificial, natural or nthetic agent flavour/palatability enhancers Icing Sugar (sucrose) Sweetening Any natural (sugars, sugar alcohols) and/or agent artificial (aspartame, saccharins, acesulfame), sweeteners Glyceryl distearate Lubricant Artificial natural or semisynthetic fats ates, glycerides, paraffin, hydrogenated vegetable oils, animal fats) Sodium chloride Humectant Potassium chloride, hyamine, aluminium silicate, sodium propionates, sodium and ium phosphates, sufites Glycerine Plasticizer Alcohols, lanolin, petrolatum, glycols, polyols, vegetable oils, hydrocarbons, hydrogenated vegetable oils Ingredient Function Examples and/or alternatives (can be used alone or in combination) Propylene Glycol Plasticizer rylates, glycols, polyols, vegetable oils, hydrocarbons, hydrogenated vegetable oils atinized starch Disintegrating Povidones, croscarmellose , sodium agent starch glycollate, cellulose, gelatine, silicon dioxide, starch Non-aqueous solvents Solvent or Dimethyl sulfoxide, N-methylpyrrolidone, or vehicles vehicle ethylene glycol, diethylene glycol monoethyl ether glycofurol, glycerol formal, acetone, alcohol, tetrahydrofurfuryl alcohol, diglyme, dimethyl isosorbide, ethyl lactate Buffering agents Buffer Citric acid, tartaric acid and other acidifying , sodium carbonate, sodium bicarbonate, sodium citrate, other carbonates, other alkalizing agents Colouring agent Colour Any natural or artificial ant Preservatives Preserve Acids, alcohols, phenols, parabens, sorbates, , phenylmercury salts In one embodiment the chewable formulation comprises one or more s.

A filler may be used to increase the total mass of the chewable formulation to a manageable size. The filler may also modify texture, have taste masking abilities or be a sweetener, a disintegrant, a binder, or a humectant, for example.

In some embodiments the filler is selected from ose powders (for example, see the Arbocel range such as Arbocel M80), soy protein powder, soy grits, silicon dioxide, wheat germ, or any combination of any two or more thereof.

In one embodiment the use of the filler absorbs any excess oils and fats, melted during extrusion, and prevents oil leakage.

In one embodiment a ation of s are used in the formulation. In an alternate embodiment a combination of one or more fillers is used with one or more diluents. In an alternate ment a combination of diluents are used in the ation.

For example, one or more diluents may be used in combination with a cellulose powder such as Arbocell M80. Examples of diluents include starches and their derivatives (e.g. hydrogenated starch hydrosylate), celluloses and their derivatives (e.g. cellulose acetate), protein matrices (soy n, dextrates, wheat gluten, whey, corn cob, corn gluten), carbohydrates (e.g. maltodextrin, polydextrose), sugars and sugar alcohols (glucose, lactose, fructose, maltose, dextrose, sucrose, maltitol, xylitol, isomalt, mannitol), tes, calcium phosphates, calcium sulfate, dextrates, kaolin, ium carbonate, polymethacrylates, talc, salts (e.g. sodium chloride) or any combination of any two or more thereof.

In one ment the diluents may also serve a role in fat absorption, disintegration, binding, ing nutrition, lubrication or any combination of any two or more thereof. The diluent may also be used for taste masking or ing texture, for example.

In one embodiment the composition comprises 2, 4, 6, 8, 10, 12, 14, 16, 18, , 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, or 90% by weight filler, diluent or filler and diluent, and useful ranges may be selected between any of these values (for example, from about 2 to about 40, about 2 to about 36, about 2 to about 30, about 2 to about 24, about 2 to about 22, about 2 to about 28, about 2 to about 24, about 2 to about 20, about 2 to about 4, about 4 to about 40, about 4 to about 30, about 4 to about , about 4 to about 10, about 8 to about 40, about 8 to about 36, about 8 to about 30, about 8 to about 28, about 8 to about 22, about 8 to about 18, about 8 to about 14, about 10 to about 40, about 10 to about 32, about 10 to about 26, about 10 to about 20, about 16 to about 40, about 16 to about 32, about 16 to about 24, about 16 to about 20, about 22 to about 40, about 22 to about 36, about 22 to about 30, about 22 to about 24, about 28 to about 40, about 28 to about 36, about 28 to about 30, about 32 to about 40, about 32 to about 34, about 24 to about 40, about 24 to about 38 or about 38 to about 40% by weight filler, diluent or filler and diluent).

In one embodiment the formulation ses about 15% by weight filler, diluent or filler and t.

In one embodiment the chewable formulation comprises one or more binders.

Binding agents may be used to improve the binding properties of the powdered mass, to assist the formation of compact dosage units.

Any suitable binder known in the art may be used. In one embodiment the binder is selected from gums such as xanthan gum or guar gum, alginates, celluloses and their tives such as methylcellulose or microcrystalline cellulose, fats or lipids, starches and their derivatives, dextrins, celluloses and their derivatives, povidones, silicates, mineral oils, vegetable oils, polymethacrylates, polyethylene oxides, gums, waxes, chitosan, polycarbophil, agar, or carbomers, or any combination of any two or more thereof.

In some embodiments the binder is a dry binder such as Methocel A15 Premium (methylcellulose) and Avicel crystalline cellulose + calcium phosphate c). The ors have found that both these binders have good y to bind dry powders and undergo direct compaction.

Surprisingly, contrary to their traditional use, fats or lipids have also been found to be useful in the present invention as binders. The fats or lipids melt at extrusion temperature and harden again xtrusion, binding the chew mass in a lipid matrix.

Fats and lipids that are solid at room temperate but melt at temperatures above 30 C (preferably 40-90C) can also be used as a binder. For example, yl distearate NF/ glycerol distearate, having a melting point between 50-60C was found by the inventors to be useful in the present invention. Several other fats, such as glycerol monostearate (melting point: 54-64 C), behenoyl polyoxylglycerides NF (drop point: 60-74 C ), hydrogenated coconut oil or hard fat (melting point: 42-44 C ) and shortening (melting point 46-48 C) may also be useful.

In one embodiment the formulation comprises 0.1, 0.2, 0.3, 0.5, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 0, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50% % by weight binder, and useful ranges may be selected between any of these values (for example, from about 0.1 to about 50, from about 0.1 to about 40, from about 0.1 to about 30, from about 0.1 to about 25, from about 0.1 to about 20, from about 0.1 to about 15, about 0.1 to about 12, about 0.1 to about 7, about 0.1 to about 5, about 0.1 to about 1, about 0.1 to about 0.6, about 0.1 to about 0.5, about 0.1 to about 0.4, about 0.3 to about 50, about 0.3 to about 40, about 0.3 to about 30, about 0.3 to about 25, about 0.3 to about 20, about 0.3 to about 15, about 0.3 to about 12, about 0.3 to about 10, about 0.3 to about 7, about 0.3 to about 6, about 0.3 to about 5, about 03 to about 1, about 0.3 to about 0.8, about 0.5 to about 50, about 0.5 to about 40, about 0.5 to about 30, about 0.5 to about 25, about 0.5 to about 20, about 0.5 to about 15, about 0.5 to about 13, about 0.5 to about 10, about 0.5 to about 7, about 0.5 to about 6, about 0.5 to about 4, about 0.5 to about 1, about 0.5 to about 0.9, about 1 to about 50, about 1 to about 40, about 1 to about 30, about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 12, about 1 to about 10, about 1 to about 7, about 1 to about 6, about 3 to about 50, about 3 to about 40, about 3 to about , about 3 to about 25, about 3 to about 20, about 3 to about 15, about 3 to about 13, about 3 to about 10, about 3 to about 8, about 3 to about 7, about 3 to about 5, about 5 to about 50, about 5 to about 40, about 5 to about 30, about 5 to about 25, about 5 to about 20, about 5 to about 15, about 5 to about 12, about 5 to about 10, about 5 to about 7, about 5 to about 6, about 8 to about 50, about 8 to about 40, about 8 to about , about 8 to about 25, about 8 to about 20, about 8 to about 15, about 8 to about 12, about 8 to about 10, about 11 to about 50, about 11 to about 40, about 11 to about 30, about 11 to about 25, about 11 to about 20, about 11 to about 15, about 11 to about 12 or about 13 to about 15% by weight binder).

In one embodiment, the formulation comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, or 50% weight binder and/or filler, and useful ranges may be selected between any of these values.

In one embodiment the binder is a gum such as guar gum or xanthan gum and is present in the formulation at about 0.2 to about 0.6, and more ably 0.25 to about 0.5% by weight.

The binder may be added in the form of a liquid or solid. Filler-binders are typically in solid form.

In one embodiment the chewable formulation comprises one or more sweeteners.

Sweetening agents may be used to improve the palatability of the chewable treats.

Any le sweetener known in the art may be used. In one embodiment the sweetener may be a natural sweetener such as e, fructose, sucrose (e.g. icing sugar), lactose, dextrose, glycerol, sorbitol, l, maltitol, lactitol, glycerol, an artificial sweetener such as aspartame, a saccharin, acesulfame, sodium cyclamate, or any combination of any two or more thereof. In another ment, the sweetener is selected from glucose, fructose, sucrose, lactose, dextrose, ol, sorbitol, xylitol, maltitol, lactitol, glycerol, aspartame, a saccharin, fame, sodium cyclamate, stevia, rebaudioside A, thaumatin, sucralose, licorice and its derivatives, alitame, neotame, neohesperidin, or dihydrochalcone, or any ation of any two or more thereof.

In one embodiment, the chewable formulation comprises one or more palatability enhancers. Palatability ers improve the palatability of the chewable treats. Advantageously, palatability enhancers may improve the palatability of chewable formulations comprising bitter, acrid, obnoxious, unpleasant, or ise table nutritional or pharmaceutically active agents.

In one embodiment, the chewable formulation comprises 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, , 26, 27, 28, 29, or 30% by weight palatability enhancer, and useful ranges may be selected between any of these values (for example, from about 0.5 to about 30, from about 0.5 to about 25, from about 0.5 to about 20, from about 0.5 to about 15, about 1 to about 30, about 1 to about 25, about 1 to about 20, about 1 to about 15, about 5 to about 30, about 5 to about 25, about 5 to about 20, or about 5 to about 15).

In one embodiment, the palatability enhancer is a taste masking agent, a flavour potentiator, an aroma modifier, or a taste modifier, or any combination of any two or more thereof.

In one embodiment, the taste modifier is a bitter blocker.

In one embodiment, the bitter blocker is selected from polyethoxylated glycerol fatty acid esters, such as polyethylated castor oil (e.g. cremphor), cyclodextrins (e.g. odextrin), ones (e.g. homoeriodictyol sodium salt), alkaline earth metal salts (e.g. zinc sulphate, magnesium sulphate), or celluloses and their derivatives (e.g. carboxymethylcellulose sodium salt), or any combination of any two or more thereof.

In one embodiment, the flavour potentiator is a sweetness enhancer.

In one ment, the sweetness enhancer is selected from pyridinium salts (e.g. alapyridaine), substituted benzoic acids (e.g. 2,4-dihydroxybenzoic acid), and positive allosteric modulators.

In one embodiment, the taste masking agent is ed from polyethoxylated glycerol fatty acid esters, such as polyethylated castor oil (e.g. hor), fats, or lipids, or any combination of any two or more thereof.

In one embodiment, the aroma modifier is selected from a r oil or flavour concentrate.

The inventors have also found that in, typically used as a plasticizer and humectant, may also have additional sweetening property.

In one embodiment the ation comprises 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80% by weight sweetener, and useful ranges may be selected between any of these values (for e, from about 0.1 to about 80, from about 0.1 to about 70, from about 0.1 to about 60, from about 0.1 to about 50, from about 0.1 to about 40, from about 0.1 to about 45, from about 0.1 to about 30, from about 0.1 to about 25, from about 0.1 to about 20, from about 0.5 to about 80, from about 0.5 to about 70, from about 0.5 to about 60, from about 0.5 to about 50, from about 0.5 to about 40, from about 0.5 to about 45, from about 0.5 to about 30, from about 0.5 to about 25, from about 0.5 to about 20, from about 1 to about 80, from about 1 to about 70, from about 1 to about 60, from about 1 to about 50, from about 1 to about 40, from about 1 to about 45, from about 1 to about 30, from about 1 to about 25, from about 1 to about 20, from about 5 to about 30, about 5 to about 25, about 5 to about 20, about 5 to about 25, about 5 to about 20, about 8 to about 30, about 8 to about 25, about 8 to about 20, about 8 to about 14, about 8 to about 12, about 10 to about 30, about 10 to about 25, about 10 to about 21, about 10 to about 14, about 14 to about 30, about 14 to about 25, about 14 to about 21, about 14 to about 19, about 15 to about 30, about 15 to about 26, about 15 to about 20, about 18 to about 30, about 18 to about 27, about 18 to about 25, about 18 to about 20, about 22 to about 30, about 22 to about 18, about 22 to about 25, about 25 to about 30 or about 26 to about 30% by weight sweetener).

In one embodiment, the chewable formulation comprises one or more flavouring agents, palatability enhancers, a taste masking agents, or aroma modifiers, or any combination of any two or more thereof.

In one embodiment the formulation comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25% by weight flavouring agent, palatability enhancers, a taste masking agents, or aroma modifiers, or any combination of any two or more thereof, and useful ranges may be selected between any of these values.

In one embodiment the chewable formulation comprises one or more flavouring agents.

Flavouring agents may be used to improve the palatability of the chewable s. Any type of flavouring agent can be used ed it improves the palatability of the product, typically by ing either its taste and/or smell. Use of a flavouring agent may also assist dose compliance. Flavours can be natural (derived from animal or plant s), semi synthetic, or artificial. In one embodiment, the flavouring agent is an artificial flavouring agent, semi-synthetic flavouring agent, a natural flavouring agent, or nature cal flavouring agent.

The flavouring agent may be solid, semi-solid or liquid. For e, the flavouring agent may be in the form of a powder, granules, a gel, beads, a liquid, a trate or a mince.

The flavouring agent used may depend on animal for which the formulation is intended. For example, a meat flavoured flavouring agent may be used for a formulation intended for administration to a dog, while a fruit (e.g. apple) flavoured flavouring agent may be used for a formulation intended for administration to a horse.

The flavouring agent may, for e, have a sweet, fruity, dairy, meat, poultry, seafood, or plant extract flavour. Any suitable ring agent may be used.

In one embodiment, the flavouring agent is fruit, meat (e.g. pork, chicken, beef, fish), vegetable, dairy, honey, or plant derived, or is artificial.

Examples of flavouring agents include beef flavour, artificial beef type flavour, beef mince, pork liver powder, cheese flavour, roast chicken hickory smoke, stewed beef flavoring, chicken fat, roast pork, roast chicken flavour, savoury flavouring, fish flavouring, butter caramel, a, creamy vanilla, apple, sweet apple, marshmallow, citrus, plant t flavour oils, honey, dairy flavouring agents, bacon, tuna fish, and the like.

In one ment the flavouring agent is selected from artificial beef type flavour, beef mince, pork liver powder, cheese flavour, roast chicken hickory smoke, or any combination of any two or more thereof. Other flavouring agents known in the art may also be used.

In one embodiment the formulation comprises 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25% by weight flavouring agent, and useful ranges may be selected between any of these values (for example, from about 0.1 to about 25, from about 0.1 to about , from about 0.1 to about 15, from about 0.1 to about 13, from about 0.1 to about 10, from about 0.1 to about 8, from about 0.1 to about 5, 0.2 to about 25, from about 0.2 to about 20, from about 0.2 to about 15, from about 0.2 to about 13, from about 0.2 to about 10, from about 0.2 to about 8, from about 0.2 to about 5, from about 0.5 to about , from about 0.5 to about 20, from about 0.5 to about 15, from about 0.5 to about 13, from about 0.5 to about 10, from about 0.5 to about 8, from about 0.5 to about 5, from about 1 to about 25, from about 1 to about 20, from about 1 to about 15, about 1 to about 13, about 1 to about 10, about 1 to about 8, about 1 to about 5, about 1 to about 4, about 2 to about 15, about 2 to about 10, about 2 to about 9, about 2 to about 6, about 2 to about 5, about 2 to about 4, about 5 to about 15, about 5 to about 12, about to about 10, about 5 to about 8, about 8 to about 15, about 8 to about 10, about 10 to about 15, about 12 to about 15 or about 13 to about 15% by weight ring agent).

The amount of used depends on the flavouring agent.

In one embodiment the chewable ation comprises one or more plasticizers.

Plasticizers may be used to the formulation to improve its plasticity, and malleability. Plasticizers make the extrusion feel e and easy to shape.

In one embodiment the cizer may be selected from alcohols, glycols (such as ene glycol), lanolin, wool fat, liquid paraffin, mineral oil, petrolatum, benzyl phenylformate, butanol, diethyl phthalate, ol, polyethylene glycol, propylene glycol, sorbitol, triacetin, benzyl phenyl formate, PLGA, methacrylates, phthalates, acetyltributyl citrate, acetyltriethyl citrate, castor oil, dibutyl sebacate, tributyl citrate, triethyl citrate, or any combination of any two or more thereof. Other plasticizers known in the art may also be used.

Surprisingly, contrary to their traditional use, fats or lipids have also been found to be useful in the present invention as plasticizers. Fats or lipids used in the formulation melt at the extrusion temperature to function as a plasticizer.

The inventors have also ined that plasticizers such as propylene glycol and glycerine can have multiple roles, as they can also function as humectants and reduce water activity of the chewable formulation.

In one embodiment the chewable formulation comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45% by weight plasticizer, and useful ranges may be selected between any of these values (for example, from about 5 to about 45, from about 5 to about 40, from about 5 to about 35, from about 5 to about 30, about to about 26, about 5 to about 22, about 5 to about 15, about 5 to about 12, about 5 to about 12, about 5 to about 8, about 8 to about 45, about 8 to about 40, about 8 to about , about 8 to about 30, about 8 to about 28, about 8 to about 25, about 8 to about 21, about 8 to about 16, about 8 to about 12, about 10 to about 45, about 10 to about 40, about 10 to about 35, about 10 to about 30, about 10 to about 26, about 10 to about 22, about 10 to about 18, about 10 to about 14, about 14 to about 45, about 14 to about 40, about 14 to about 35, about 14 to about 30, about 14 to about 25, about 14 to about 20, about 18 to about 45, about 18 to about 40, about 18 to about 35, about 18 to about 30, about 18 to about 26, about 18 to about 23, about 18 to about 20, about 20 to about 45, about 20 to about 40, about 20 to about 35, about 20 to about 30, about 20 to about 25, about 22 to about 45, about 22 to about 40, about 22 to about 35, about 22 to about 30, about 22 to about 25, about 25 to about 45, about 25 to about 40, about 25 to about 35, about 25 to about 30 or about 27 to about 30% by weight plasticizer).

In one embodiment, the placticiser is a liquid at standard temperature and pressure.

In one embodiment the chewable formulation comprises one or more humectants.

Humectants may be used to reduce the water activity. Humectants bind any water, if present, to themselves, so that free moisture is unavailable for microbial contamination or chemical breakdown of active ingredient. Humectants may also prevent the t from drying out.

In one embodiment the humectant is ed from sodium and potassium de, benzalkonium chloride, aluminium silicate, sodium nates, sodium and potassium phosphates, sugars, sulfites, hydrogenated starch hydrosylate, etc. Liquid humectants include, but are not limited to, glycols, polyols, sugar alcohols, vegetable oils and mineral oil, hydrogenated vegetable oils, hydrocarbons, triacetin, liquid paraffin, or any combination of any two or more thereof. Other humectants known in the art may also be used.

The humectants may be in the form of a solid or liquid. In one embodiment the humectant is in a solid form.

The inventors have surprisingly found that propylene glycol and glycerin also function as humectants and reduce the water ty of the chewable treats. As such, in certain embodiments wherein the chewable formulation comprises propylene glycol and/or glycerin, it may not be ary to include an antimicrobial agent in the formulation to prevent microbial contamination.

In some embodiments the chewable formulation may also comprise solid humectants, such as salt and sugar. These humectants work together to reduce the overall water activity of the dosage unit and make it less susceptible to microbial contamination and water induced chemical degradation.

In one embodiment the le formulation comprises 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90% by weight humectant, and useful ranges may be selected between any of these values (for example, from about 0.2 to about 90, from about 0.2 to about 80, from about 0.2 to about 70, from about 0.2 to about 60, from about 0.2 to about 50, from about 0.2 to about 40, from about 0.2 to about 30, from about 0.2 to about 20, from about 0.2 to about 10, from about 0.2 to about 5, about 0.2 to about 4, about 0.2 to about 2, about 0.2 to about 1, about 0.2 to about 0.7, about 0.6 to about 90, about 0.6 to about 80, about 0.6 to about 70, about 0.6 to about 60, about 0.6 to about 50, about 0.6 to about 40, about 0.6 to about 30, about 0.6 to about 20, about 0.6 to about 10, about 0.6 to about 5, about 0.6 to about 4, about 0.6 to about 2, about 0.6 to about 1, about 0.6 to about 0.8, about 0.8 to about 90, about 0.8 to about 80, about 0.8 to about 70, about 0.8 to about 60, about 0.8 to about 50, about 0.8 to about 40, about 0.8 to about 30, about 0.8 to about 20, about 0.8 to about 10, about 0.8 to about 5, about 0.8 to about 4, about 0.8 to about 2, about 0.8 to about 1, about 1 to about 90, about 1 to about 80, about 1 to about 70, about 1 to about 60, about 1to about 50, about 1 to about 40, about 1 to about 30, about 1 to about 20, about 1 to about 10, about 1 to about 5, about 1 to about 4, about 1 to about 3, about 1 to about 2, about 2 to about 90, about 2 to about 80, about 2 to about 70, about 2 to about 60, about 2 to about 50, about 2 to about 40, about 2 to about 30, about 2 to about 20, about 2 to about 10, about 2 to about 5, about 2 to about 4, about 3 to about 90, about 3 to about 80, about 3 to about 70, about 3 to about 60, about 3 to about 50, about 3 to about 40, about 3 to about 30, about 3 to about 20, about 3 to about 10, about 3 to about 5, about 5 to about 90, about to about 80, about 5 to about 70, about 5 to about 60, about 5 to about 50, about 5 to about 40, about 5 to about 30, about 5 to about 20, about 5 to about 10, about 10 to about 90, about 10 to about 80, about 10 to about 70, about 10 to about 60, about 10 to about 50, about 10 to about 40, about 10 to about 30, about 10 to about 20, about 15 to about 90, about 15 to about 80, about 15 to about 70, about 15 to about 60, about 15 to about 50, about 15 to about 40, about 15 to about 30, or about 15 to about 20% by weight humectant).

In one embodiment, the le formulation comprises less than about 45, 40, 35, 30, 25, 20, 15, 10, or 5% liquid humectant.

In one embodiment the chewable formulation comprises one or more lubricants.

Lubricants may be used to assist the formulation to slip through the extruder without on.

In one embodiment lipids, fat or lipids and fats are added to the formulation to e lubrication during extrusion.

The fats and lipids used are typically solid at room temperature, but melt partially or completely under extrusion conditions. The melted fats/lipid further e binding and plasticity of the chew formulation. The plastic extrusion feed is then shaped in the extruder die under very high pressure to form the chewable treats. Once out of the extruder, the fats/lipids solidify again and the chewable treats harden, to compact semisoft dosage units.

In one embodiment the fats and lipids are selected from shortening, tallow, tes, glyceryl distearate, glycerol monostearate, behenoyl yglyceride, hydrogenated coconut oil, hard fat, or any combination of any two or more thereof. Other ipids known in the art may also be used.

In one embodiment the chewable formulation comprises 2, 3, 4, 5, 6 ,7 8, 9, , 11, 12, 13, 14, 15, 16, 17, 18% by weight lubricant, and useful ranges may be selected between any of these values (for e, from about 2 to about 18, about 2 to about 16, about 2 to about 14, about 2 to about 12, about 2 to about 10, about 2 to about 8, about 2 to about 6, about 4 to about 18, about 4 to about 17, about 4 to about 14, about 4 to about 12, about 4 to about 10, about 4 to about 8, about 5 to about 18, about 5 to about 17, about 5 to about 16, about 5 to about 12, about 5 to about 10, about 5 to about 7, about 7 to about 18, about 7 to about 15, about 7 to about 14, about 7 to about 12, about 7 to about 10, about 9 to about 18, about 9 to about 16, about 9 to about 14, about 9 to about 11, about 10 to about 18, about 10 to about 17, about 10 to about 14, about 10 to about 12, about 12 to about 18, about 12 to about 17,12 to about 14, about 15 to about 18, about 15 to about 17 or about 16 to about 18% by weight lubricant).

In one embodiment the chewable formulation comprises an antioxidant.

Antioxidants may be used to protect the active ingredient from oxidation.

In one embodiment the antioxidant is selected from propyl gallate, ascorbic acid and its derivatives, sodium formaldehyde sulfoxylate, malic acid, fumaric acid, editic acid, thiols, polyphenols, sodium EDTA, sodium ascorbate, sodium metabisulfite, butylated hydroxytoluene, ted hydroxyanisole, or natural substances such as flavanoids, erols, carotenes, ne, or any combination of any two or more thereof. Other antioxidants known in the art may also be used.

The inventors have surprisingly found that the use of yl palmitate and -tocopherols are synergistic in the ation of the present invention.

The amount of antioxidant used may depend on, for example, the nutritionally or pharmaceutically active agent present in the formulation and its concentration.

In one embodiment the le formulation comprises about 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5% by weight antioxidant, and useful ranges may be selected between any of these values (for example, from about 0.0005 to about 5, from about 0.0005 to about 3, from about 0.0005 to about 1, from about 0.0005 to about 0.5, from about 0.001 to about 5, from about 0.001 to about 3, from about 0.001 to about 2, from about 0.001 to about 1, from about 0.001 to about 0.5, from about 0.001 to about 0.2, from about 0.005 to about 5, from about 0.005 to about 3, from about 0.005 to about 1, from about 0.005 to about 0.5, from about 0.005 to about 0.2, from about 0.01 to about 5, from about 0.01 to about 3, from about 0.01 to about 1, from about 0.01 to about 0.5, from about 0.01 to about 0.2 by weight antioxidant).

In one embodiment, the chewable formulation comprises a surfactant.

In one embodiment, the formulation comprises about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20% surfactant by weight, and useful ranges may be ed between any of these values (for example, from about 2 to about 10% surfactant by weight).

In one embodiment, the surfactant is selected from propylene glycol esters (e.g. propylene glycol monocaprylate), PEGs, PEG esters, fatty acid glycerides (e.g. lauroyl glycerides), and anionic surfactants (e.g. sodium lauryl sulfate).

In one embodiment, the chewable formulation comprises a solubility enhancer, bioavailability enhancer, or a solubility enhancer and bioavailability enhancer.

The solubility enhancer and/or bioavailability enhancer enhances the water solubility and/or ilability of the nutritional or pharmaceutically active agent in the animal to which the formulation is to be administered.

In one embodiment, the le formulation comprises about 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15% by weight solubility enhancer, bioavailability enhancer, or solubility enhancer and bioavailability enhancer, and useful ranges may be ed between any of these values (for example, from about 0.01 to about 15, from about 0.01 to about 10, from about 0.01 to about 8, from about 0.01 to about 6, from about 0.01 to about 5, from about 0.1 to about 15, from about 0.1 to about 10, from about 0.1 to about 8, from about 0.1 to about 6, from about 0.1 to about , from about 0.5 to about 15, from about 0.5 to about 10, from about 0.5 to about 8, from about 0.5 to about 6, from about 0.5 to about 5, from about 1 to about 15, from about 1 to about 14, from about 1 to about 13, from about 1 to about 12, from about 1 to about 11, from about 1 to about 10, from about 1 to about 9, from about 1 to about 8, from about 1 to about 7, from about 1 to about 6, or from about 1 to about 5% solubility enhancer, bioavailability enhancer, or solubility enhancer and bioavailability enhancer by weight). The amount of lity or bioavailability enhancing agent used depends on the nutritional or pharmaceutically active agent, and the amount in which the nutritional or pharmaceutically active agent is present.

In one embodiment, the solubility enhancer is selected from surfactants, complexing agents, buffers, or ionic salts, or any ation of any two or more thereof.

In one embodiment, the solubility enhancer is selected from sodium lauryl sulphate, polysorbates, spans, polyethylene glycols, bile salts, lecithin, phospholipids, poloxamers, polyoxyl 35 castor oil, medium chain mono- and diglycerides, propylene glycol monolaurate, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, tocopheyl polyethylene glycol succinate, ylhydroxystearate, lauroyl polyoxyl-32 glycerides , nonionic ck copolymers, polyoxyethylene (8) caprylic/capric ides, PEG-40 hydrogenated castor oil, diethylene glycol hyl ether and caprylocaproyl macrogol glycerides, or any combination of any two or more thereof. Any other suitable solubility enhancers known in the art may be used.

In one embodiment, the bioavialbility enhancer is penetration enhancer.

In one embodiment, the bioavailability enhancer is a naturally or herbally derived ilability enhancer.

In one embodiment, the bioavailability enhancer is selected from quercetin, genistein, lysergol, naringin, sinomenine, piperine, glycyrrhizin, nitrile glycoside, cuminum cyminum, niaziridin, piperine, or allicine.

In one ment, the chewable formulation comprises one or more complexing agents.

In one embodiment, the ional or pharmaceutically active agent is xed or conjugated with one or more complexing agents.

In one ment, the complexing agent is selected from EDTA, choleic acid, cyclodextrins (e.g. β-cyclodextrin), cyclic glucose ers, or polymers such as polethylene glycols, methyl cellulose, carboxy methyl ose and polyvinylpyrollidine, or any combination of any two or more thereof.

In one embodiment, the chewable formulation comprises about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70 or 80% complexing agent by weight, and useful ranges may be selected between any of these values (for example, from about 0.1% to about 30% complexing agent by weight). The amount used depends on the concentration of API and its affinity for the complexing agent.

In one embodiment, the molar ratio of API : complexing agent is about 4:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10, and useful ranges may be ed between any of these values (for example, from about 1:1 to about 1:10.

In one embodiment, the chewable formulation comprises one or more coating .

In one embodiment, the nutritional or pharmaceutically active agent, optionally in granular form, are coated with the one or more coating agents.

In one embodiment, the chewable formulation comprises about 1% to about % coating agent by weight of the nutritional or pharmaceutically active agent.

In one embodiment, the coating agent is selected from polyethylene glycols, a wax, or a fatty acid, or a combination of any two or more thereof.

In one ment, the chewable formulation comprises a ueous t, for example glycerol formal. The non-aqueous solvent may solubilise or enhance solubilization of the nutritional or pharmaceutically active agent. The non- aqueous solvent may also enhance the extrudability of the formulation and the tency and texture of the chewable product.

In one embodiment, the chewable formulation comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25% by weight non-aqueous solvent or vehicle, and useful ranges may be selected between any of these values (for e, from about 1 to about 25, from about 1 to about 20, from about 1 to about 18, from about 1 to about 16, from about 1 to about 15, from about 1 to about 14, from about 1 to about 13, from about 1 to about 12, from about 1 to about 11, from about 1 to about 10, from about 1 to about 9, from about 1 to about 8, from about 1 to about 7, from about 1 to about 6, from about 1 to about 5, from about 2 to about 25, from about 2 to about 20, from about 2 to about 18, from about 2 to about 16, from about 2 to about 14, from about 2 to about 12, from about 2 to about 10, from about 2 to about 8, from about 2 to about 6, from about 5 to about 25, from about 5 to about 20, from about 5 to about 15, or from about 5 to about 10 non-aqueous solvent or vehicle).Those skilled in the art will appreciate that the amount of ueous solvent or vehicle used must be veterinary or pharmaceutically acceptable.

The non-aqueous solvent or vehicle is typically an organic t, which is pharmaceutically acceptable and chemically and biologically inert in the amount used. In one embodiment, the organic solvent is selected from dimethyl sulfoxide, N-methyl pyrrolidone, ethylene glycol, diethylene glycol monoethyl ether urol, glycerol formal, acetone, alcohol, tetrahydrofurfuryl l, e, dimethyl bide, and ethyl lactate.

Further es of organic solvents include alcohols (e.g. glycerol formal, methanol, ethanol, n-propanol, and iso-propanol), glycols (e.g. propylene glycol), ketones (e.g. acetone, methyl ethyl ketone), amide (e.g. dimethyl formamide), ethers (e.g. dimethyl isosorbide, 1,4-dioxane, diethyl ether, ydrofuran, and tert-butyl methyl ether), halogenated solvents (e.g. dichloromethane and chloroform), sulfur containing solvents (e.g. dimethyl sulfoxide), aromatic hydrocarbons, aliphatic hydrocarbons (e.g. hexane and cyclohexane), esters (e.g. glycerol triacetate, ethyl acetate), carbonates (e.g. propylene carbonate), and nitriles (e.g. acetonitrile). Other suitable non-aqueous ts will be nt to those skilled in the art.

In one embodiment the chewable formulation comprises a colouring agent which may be used to improve the aesthetic appeal of the dosage units.

In one ment the colours are natural or artificial and may be ed from l or brown oxide for example. Other colouring agents known in the art may also be used.

In one embodiment the chewable formulation comprises a disintegrating agent. A disintegrating agent may be used to enable the chew to break down on contact with water to quickly release the active ingredient. This minimizes the risk of the chewable treat travelling unabsorbed h the gastrointestinal tract (GIT).

In one embodiment the disintegrating agent is selected from povidones, croscarmellose , sodium starch glycollate, celluloses and their derivatives, starches and their derivatives, gelatin, silicon dioxide, or any ation of any two or more thereof. Other disintegrating agents known in the art may also be used.

In one embodiment the formulation comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30% by weight disintegrating agent, and useful ranges may be selected between any of these values (for example, from about 1 to about 30, from about 1 to about 25, from about 1 to about 20, from about 1 to about 15, about 1 to about 13, about 1 to about 10, about 1 to about 8, about 1 to about 5, about 1 to about 4, about 2 to about 30, about 2 to about , about 2 to about 20, about 2 to about 15, about 2 to about 10, about 2 to about 9, about 2 to about 6, about 2 to about 5, about 2 to about 4, about 5 to about 30, about 5 to about 25, about 5 to about 20, about 5 to about 15, about 5 to about 12, about 5 to about 10, about 5 to about 8, about 8 to about 30, about 8 to about 25, about 8 to about , about 8 to about 15, about 8 to about 10, about 10 to about 30, about 10 to about , about 10 to about 20, about 10 to about 15, about 12 to about 30, about 12 to about , about 12 to about 20, about 12 to about 15, about 13 to about 30, about 13 to about , about 13 to about 20, or about 13 to about 15% by weight disintegrating agent).

In one embodiment the chewable formulation comprises preservatives, buffering agents or preservatives and buffering agents. Preservatives may be used to t microbiological contamination and improve stability of the drug.

In one embodiment the preservative is selected from acids, alcohols, phenols, ns, sorbates, thiols, phenylmercury salts, or any combination of any two or more thereof. Other preservatives known in the art may also be used.

In one embodiment a buffering agent may be added to adjust the pH of the formulation. This can sometimes help to improve the stability of certain active ingredients.

As mentioned previously, in some embodiments fats, lipids or fats and lipids are used in the formulation of the t ion. Any fats or lipids that are solid at room temperature, but melt above 30 C, preferably between 40-90 C can be used.

Fats/lipids on as ants, binders and plasticizers in this formulation. These include, but are not limited to stearates, glycerides, phospholipids, tes, waxes, fatty acid esters, hydrogenated vegetable oils, animal fats, wool fat, hard fat, or any combination of any two or more thereof.

In one embodiment the chewable formulation comprises 2, 3, 4, 5, 6 ,7 8, 9, , 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25% by weight fats, lipids or fats and lipids, and useful ranges may be selected between any of these values (for example, from about 2 to about 25, from about 2 to about 20, from about 2 to about 18, about 2 to about 16, about 2 to about 14, about 2 to about 10, about 2 to about 8, about 2 to about 6, about 4 to about 25, about 4 to about 20, about 4 to about 18, about 4 to about 17, about 4 to about 14, about 4 to about 12, about 4 to about 10, about 4 to about 8, about 5 to about 25, about 5 to about 20, about 5 to about 18, about 5 to about 17, about 5 to about 16, about 5 to about 12, about 5 to about 10, about 5 to about 7, about 7 to about 25, about 7 to about 20, about 7 to about 18, about 7 to about 15, about 7 to about 14, about 7 to about 12, about 7 to about 10, about 9 to about 25, about 9 to about 20, about 9 to about 18, about 9 to about 16, about 9 to about 14, about 9 to about 11, about 10 to about 25, about 10 to about 20, about 10 to about 18, about 10 to about 17, about 10 to about 14, about 10 to about 12, about 12 to about 25, about 12 to about 20, about 12 to about 18, about 12 to about 17,12 to about 14, about to about 25, about 15 to about 20, about 15 to about 18, about 15 to about 17, about 16 to about 25, about 16 to about 20, or about 16 to about 18% by weight fats, lipids or fats and lipids).

The chewable formulation may other conventional inert ingredients known in the art for use in chewable formulations.

In one embodiment, the chewable formulation comprises one or more food ingredients.

In one embodiment, the food ingredient is selected from oils (e.g. Soybean oil, Canola Oil, Peanut Oil, Palm Oil, Cod-liver oil), extracts (e.g. Rosemary extract, Grape extract, Vanilla extract, Citrus or lemon balm extract, Malt extract, or Other plant or ble, fruit based extracts), flours and starches (e.g. Oat Flour, Pea Flour, Pearled Barley Flour, Rice flour, Wheat Flour, Corn starch, Tapioca Starch, Potato starch or flour, Rye Grain flour, Cereal Flour), and others such as Milk Protein, Dried whole milk or milk products, Bran, Carrageenan, Pectin, and Menthol.

The ingredients used in the formulation are typically food grade quality or higher (e.g. generally ed as safe (GRAS) and/or ceutical grade). Mixtures of ingredients of different grades may be used.

As described herein, some of the ingredients used in the le formulation can be multifunctional. For example, sucrose can be used as a filler/diluent, binder and as a sweetening agent, and starches can be used as a filler/diluent, binder and as a egrating agent.

In one embodiment, the formulation comprises about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40% by weight liquid ingredients, and useful ranges may be ed between any of these values (for example, from about 10 to about 40, from about 10 to about 35, from about 10 to about 30, from about 10 to about 25, from about 15 to about 40, from about 15 to about 35, from about 15 to about 30, or from about 15 to about 25).

In another aspect the invention relates to a method of manufacturing a shelf stable le formulation 8 comprising mixing a nutritional or pharmaceutically active agent 1 with a fat, lipid or fat and lipid 3 to obtain a first ition 4, optionally adding one or more plasticizers 5 to the first mixture to obtain a second composition 6, and extruding the first composition 4 or second composition 6 under conditions effective to at least partially melt the fat, lipid, or fat and lipid, thereby providing the chewable formulation, and wherein the method of manufacture does not e the addition of water.

In one embodiment, the fat, lipid or fat and lipid 3 acts as a plasticiser and the first composition 4 is extruded.

In one embodiment, one or more plasticisers 5 are added to the first mixture to obtain a second composition 6, and the second composition 6 is extruded 7.

In one embodiment, the extrusion 7 is carried out at a temperature and/or pressure sufficient to at least partially melt the fat, lipid, or fat and lipid.

In one embodiment, the conditions are sufficient to melt at least 10, 15, 20, , 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95% of the fat, lipid, or fat and lipid.

In one embodiment, the conditions are effective to completely melt the fat, lipid, or fat and lipid.

In one embodiment the invention s to a method of manufacturing an extruded chewable ation 8 comprising mixing a nutritional ingredient or an effective amount of a pharmaceutically active agent with a fat, lipid or fat and lipid 3 to obtain a first composition 4, adding one or more plasticizers 5 to the first e to obtain a second composition 6, ing 7 the second ition at a temperature sufficient to melt the fat and lipid, and allowing the extruded second ition to cool to room temperature thereby ing the chewable formulation 8, and wherein the method of manufacture does not include the addition of water.

In one embodiment, the nutritional or pharmaceutically active agent is, prior to the addition of the plasticiser, combined with one or more ingredients selected from:  a filler, diluent or filler and diluent,  a binder,  a sweetener,  a flavouring agent,  a humectant,  a fat, lipid or fat and lipid,  an antioxidant,  a colouring agent,  a disintegrating agent,  a preservative, buffering agent, or preservative and buffering agent,  a lubricant,  a complexing agent,  a coating agent,  a surfactant,  a solubility enhancer, bioavailability enhancer, or a solubility enhancer and a bioavailability enhancer,  a palatability enhancer, or  a non-aqueous solvent or vehicle, or  any combination of any two or more thereof to form a pre-composition 2 or first composition 4.

In one embodiment, the one or more ingredients are in a dry state. In one ment, the one or more ingredients are not in liquid form.

In one ment, the nutritional or pharmaceutically active agent is combined with the one or more ingredients, prior to the addition of the fat, lipid or fat and lipid.

In one ment the nutritional ingredient or an effective amount of a pharmaceutically active agent is first (i.e. prior to the addition of the fat, lipid or fat and lipid) combined with  a filler,  a diluent,  a sweetener,  a flavouring agent,  a binder,  a egrating agent, or  any combination of two or more of the above to form a pre-composition 2.

In one embodiment the pre-composition 2 is a dry mixture of ingredients.

In one embodiment the fat, lipid, or fat and lipid 3 are pulverised before being added.

In one embodiment a plasticiser 5 is added to the second composition.

In one embodiment, the plasticiser is in the form of a .

It should be appreciated that the fat, lipid, or fat and lipid can also act as a plasticiser. In this case, in some embodiments, following the addition of the fat, lipid, or fat and lipid, r plasticiser is not added.

In one embodiment, the method of manufacture may be carried out without applying heat. Heating during the manufacturing process may adversely impact on the stability of the nutritional or pharmaceutically active agent.

In one embodiment, the extrusion is carried out without applying heat. In such embodiments, the heat generated in the extruder due to shear is sufficient to at least partially melt the fat, lipid or fat and lipid; it is not necessary to apply heat from an external source.

In one embodiment extrusion is carried out at a temperature of about 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, or 45 C, and useful ranges may be selected between any of these values (for example, the extrusion may be carried out at a temperature from about 20 to about 45, from about 20 to about 40, from about 20 to about 30 °C). In one embodiment, the extrusion is carried out at a temperature of less than about 45, 44, 42, 40, 38, 36, 34, 32, 30, 28, 26, 24, 22, or 20 °C.

In one embodiment the extrusion is med under pressure sufficient to bind the ients er.

In one embodiment the second composition is blended prior to extrusion.

In one embodiment a planetary mixer is used to carry out the blending.

In one embodiment the extrusion is carried out as a single ion step.

In one embodiment, the method of manufacture comprises co-extruding at least one additional composition. The at least one additional composition may comprise any of the ingredients described herein with t to the first or second composition.

Co-extruding at least one additional composition es a le formulation in the form of a co-extrudate.

The plasticizers (propylene glycol and glycerin) are added to the powder mass to increase plasticity and give the powder mass a dough-like consistency.

During extrusion, the feed is subjected to a temperature and pressure under which the fats/lipids melt and bind the powders together. They also improve plasticity of the extrusion feed and lubricate it, thus preventing sticking/picking to the extruder dies.

At room temperature the extrudates cool again and become slightly harder.

The diluents and dry powder s in the extrusion feed have high fat retention ability and prevent oil leakage.

Water, or any other aqueous ient, is not used during the formulation and manufacture of chewable treats, ensuring improved physical, chemical and microbiological ity. While there may be water in the formulation, any water is present in a bound state, and not a free state.

It will be appreciated that unbound water is water that is in a free state, and can take part in, for e, hydrolysis reactions. In the present invention any water t is effectively in a bound state. This effectively means that the water is not available for chemical reactions or use, for example by microorganisms.

In one embodiment at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% by weight of any water present in the chewable formulation is present in a bound state, and useful ranges may be selected between any of these values (for e, from about 95 to about 99, about 97 to about 99, about 96 to about 99, about 96 to about 98, about 97 to about 99, about 97 to about 98 or 98 to about 99 of any water present in the chewable formulation is in a bound state).

The amount of water present in a bound state in the formulation may be determined using any suitable method known in the art. Methods for measuring free moisture/water include, for example, water activity, and loss on drying (moisture balance). Methods for measuring free and bound water include, for example, Karl r methods (e.g. KF titrators, KF oven/evaporators, moisture ), and thermogravimetric analysis (TGA). The above methods are commonly used in pharmaceutical and food ries.

It will be apparent to those skilled in the art that it may be necessary to use more than one method in combination to determine the amount of free and bound water.

One method that can be used quantify both unbound and bound moisture in the formulation is high tion TGA.

The chewable formulation ore has a low water activity (aw). A low water activity can be provided by including a sufficient amount of one or more humectants in the formulation.

In one embodiment the water activity (aw) of the chewable formulation is less than 0.60, 0.59, 0.58, 0.57, 0.56, 0.55, 0.54, 0.53, 0.52, 0.51, 0.50, 0.49, 0.48, 0.47, 0.46, 0.45, 0.44, 0.43, 0.42, 0.41, 0.40, 0.38, 0.37, 0.36, 0.35, 0.34, 0.33, 0.32, 0.31, 0.30, 0.29, 0.28, 0.27, 0.26, 0.25, 0.24, 0.23, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11, 0.10, and useful ranges may be selected between any of these values (for example, from about 0.6 to about 0.1, from about 0.6 to about 0.15, from about 0.6 to about 0.2, from about 0.6 to about 0.25, from about 0.55 to about 0.1, from about 0.55 to about 0.15, from about 0.55 to about 0.2, from about 0.55 to about 0.25, from about 0.5 to about 0.1, from about 0.5 to about 0.15, from about 0.5 to about 0.2, from about 0.5 to about 0.25, from about 0.45 to about 0.1, from about 0.45 to about 0.15, from about 0.45 to about 0.2, or from about 0.45 to about 0.25).

In one embodiment the le formulation does not dry out during storage.

In one embodiment the chewable formulations are hard and "chewy", but not brittle, and resist deformation during storage and ng.

In one ment, the chewable formulation has a chewiness, hardness, compression energy, adhesion, cohesiveness, springiness, or modulus, or any combination of any two or more thereof (as measured by the method described in Example 7) sufficient to provide a chewable texture.

In one embodiment, the chewable ation maintains a characteristic selected from chewiness, hardness, compression energy, adhesion, cohesiveness, springiness, and modulus, and any combination of any two or more thereof (as measured by the method bed in Example 7) sufficient to provide a chewable texture.

In one embodiment, the chewable formulation has a ess of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, .9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 N, and useful ranges may be selected between any of these values (for example, from about 0.1 to about 20, from about 0.1 to about 15, from about 0.1 to about 10, from about 0.1 to about 7, from about 0.5 to about 20, from about 0.5 to about 15, from about 0.5 to about 10, from about 0.5 to about 8, from about 0.5 to about 6, from about 1 to about 20, from about 1 to about 15, from about 1 to about 10, from about 1 to about 8, from about 1 to about 6, from about 2 to about 20, from about 2 to about 15, from about 2 to about 10, from about 2 to about 8, from about 2 to about 6 N.

In one embodiment, the chewable formulation has a hardness of about 1000, 950, 900, 850, 800, 750, 725, 700, 675, 650, 625, 600, 575, 550, 525, 500, 475, 450, 425, 400, 375, 350, 325, 300, 275, 250, 225, 200, 175, 150, 125, 100, 75, 50, 25, 20, , or 10 N, and useful ranges may be selected between any of these values (for example, from about 1000 to about 10, from about 1000 to about 25, from about 1000 to about 50, from about 750 to about 10, from about 750 to about 25, from about 750 to about 50, from about 500 to about 10, from about 500 to about 25, or from about 500 to about 50 N).

In one embodiment, the le formulation has a compression energy of energy of about 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, or 3000 N.mm, and useful ranges may be selected between any of these values (for example, from about 100 to about 3000, from about 100 to about 2500, from about 100 to about 2000, from about 100 to about 1750, from about 250 to about 3000, from about 250 to about 2500, from about 250 to about 2000, from about 250 to about 1750, from about 500 to about 3000, from about 500 to about 2500, from about 500 to about 2000, from about 500 to about 1900, from about 500 to about 1800, from about 500 to about 1750, from about 600 to about 3000, from about 600 to about 2500, from about 600 to about 2000, from about 600 to about 1900, from about 600 to about 1800, from about 600 to about 1750, from about 700 to about 3000, from about 700 to about 2500, from about 700 to about 2000, from about 700 to about 1900, from about 700 to about 1800, from about 700 to about 1750, from about 750 to about 3000, from about 750 to about 2500, from about 750 to about 2000, from about 750 to about 1900, from about 750 to about 1800, from about 750 to about 1750, from about 750 to about 1700, from about 750 to about 1650, from about 750 to about 1600, from about 750 to about 1550, or from about 750 to about 1500).

In one embodiment, the chewable formulation has an adhesion of about 0, - 0.5, -1, -1.5, -2, -2.5, -3, -3.5, -4, -4.5, -5, -5.5, -6, -6.5, -7, -7.5, -8, -8.5, -9, -9.5, - , -11, -12, -13, -14, -15, -16, -17, -18, -19, or -20 N.mm, and useful ranges may be selected between any of these values (for example, from about 0 to about -20, from about 0 to about -18, from about 0 to about -16, from about 0 to about -15, from about 0 to about -14, from about 0 to about -13, from about 0 to about -12, from about 0 to about -11, from about 0 to about -10, from about 0 to about -9, from about 0 to about - 8, from about 0 to about -7, from about 0 to about -6, from about -0.5 to about -20, from about -0.5 to about -18, from about -0.5 to about -16, from about -0.5 to about - , from about -0.5 to about -14, from about -0.5 to about -13, from about -0.5 to about -12, from about -0.5 to about -11, from about -0.5 to about -10, from about -0.5 to about -9, from about -0.5 to about -8, from about -0.5 to about -7, from about -0.5 to about -6, from about -1 to about -20, from about -1 to about -18, from about -1 to about -16, from about -1 to about -15, from about -1 to about -14, from about -1 to about -13, from about -1 to about -12, from about -1 to about -11, from about -1 to about -10, from about -1 to about -9, from about -1 to about -8, from about -1 to about -7, or from about -1 to about -6).

In one embodiment, the chewable formulation has a veness of about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, or 0.5, and useful ranges may be selected between any of these values (for example, from about 0.01 to about 0.5, from about 0.01 to about 0.4, from about 0.01 to about 0.3, from about 0.01 to about 0.2, from about 0.01 to about 0.1, from about 0.03 to about 0.5, from about 0.03 to about 0.4, from about 0.03 to about 0.3, from about 0.03 to about 0.2, from about 0.03 to about 0.1, from about 0.05 to about 0.5, from about 0.05 to about 0.4, from about 0.05 to about 0.3, from about 0.05 to about 0.2, or from about 0.05 to about 0.1).

In one embodiment, the chewable formulation has a iness of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40%, and useful ranges may be selected between any of these values (for example, from about 1 to about 40, from about 1 to about 35, from about 1 to about 30, from about 1 to about 25, from about 3 to about 40, from about 3 to about 35, from about 3 to about 30, from about 3 to about , from about 5 to about 40, from about 5 to about 35, from about 5 to about 30, from about 5 to about 25, from about 10 to about 40, from about 10 to about 35, from about to about 30, or from about 10 to about 25).

In one embodiment, the chewable formulation has a modulus of about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 N/mm, and useful ranges may be selected between any of these values (for example, from about 1 to about 200, from about 1 to about 150, from about 1 to about 100, from about 1 to about 75, from about 1 to about 60, from about 3 to about 200, from about 3 to about 150, from about 3 to about 100, from about 3 to about 75, from about 3 to about 60, from about 5 to about 200, from about 5 to about 150, from about 5 to about 100, from about 5 to about 75, from about 5 to about 60, from about 10 to about 200, from about 10 to about 150, from about 10 to about 100, from about 10 to about 75, from about 10 to about 60, from about 15 to about 200, from about 15 to about 150, from about 15 to about 100, from about 15 to about 75, from about 15 to about 60, from about 20 to about 200, from about 20 to about 150, from about 20 to about 100, from about 20 to about 75, from about 20 to about 60, from about 25 to about 200, from about 25 to about 150, from about 25 to about 100, from about 25 to about 75, or from about 25 to about 60).

In one embodiment the chewable formulations is capable of ring a range of drug candidates, including nutritional supplements to an animal.

In one embodiment the le formulations may have good physical and chemical stability, providing at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, , 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 months shelf life, and useful ranges may be selected n any of these values (for example, from about 12 to about 36, from about 12 to about 30, about 12 to about 26, about 12 to about 20, about 12 to about 17, about 13 to about 36, about 13 to about 30, about 13 to about 25, about 13 to about 17, about 13 to about 15, about 16 to about 36, about 16 to about 30, about to about 30, about 15 to about 30, about 15 to about 27, about 15 to about 22, about to about 19, about 14 to about 36, about 14 to about 30, about 14 to about 28, about 14 to about 22, about 14 to about 18, about 14 to about 17, about 17 to about 36, about 17 to about 30, about 17 to about 28, about 17 to about 23, about 17 to about 20, about 18 to about 36, about 18 to about 30, about 18 to about 27, about 18 to about 24, about 18 to about 22, about 20 to about 36, about 20 to about 30, about 20 to about 28, about to about 26, about 25 to about 36, about 25 to about 30, about 25 to about 28, about or about 27 to about 30 months of shelf life).

In one embodiment the chewable formulation rs at least 80% of the active ingredient loading within 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90 or 95 s, and useful ranges may be selected between any of these values (for example, for example, from about 10 to about 95, from about 10 to about 75, from about 10 to about 60, from about 10 to about 45, from about 10 to about 30, from about 15 to about 95, from about 15 to about 75, from about 15 to about 60, from about to about 45, from about 15 to about 30, from about 20 to about 95, from about 20 to about 75, from about 20 to about 60, from about 20 to about 45, from about 20 to about , from about 30 to about 95, from about 30 to about 75, from about 30 to about 60, from about 30 to about 45, from about 50 to about 95, about 50 to about 90, about 50 to about 80, about 50 to about 70, about 50 to about 60, about 55 to about 95, about 55 to about 85, about 55 to about 80, about 55 to about 70, about 60 to about 95, about 60 to about 90, about 60 to about 80, about 60 to about 70, about 65 to about 95, about 65 to about 90, about 65 to about 80, about 70 to about 95, about 70 to about 90, about 70 to about 80, about 75 to about 95, about 75 to about 90 or about 80 to about 90 minutes from delivery of the chewable ingredient to the target animal).

In one embodiment, the chewable formulation provides sustained delivery of the nutritional or pharmaceutically active ingredient over an extended period of time. In one embodiment, the active ingredient is delivered over 2, 4, 6, 8, 10, 12, 24, 48, 60, 72, 96, 120, 144, or 168 hours, and useful ranges may be selected between any of these values.

In one embodiment, the chewable formulation provides delayed delivery of the nutritional or pharmaceutically active ingredient. In one ment, delivery is delayed by about 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, or 72 hours, and useful ranges may be selected between any of these .

The rate of release of the nutritional or ceutically active agent from the chewable formulation may be modulated or controlled by, for example, the use certain controlled or sustained release agents (e.g. polymers) or by using excipients (e.g. disintegrants) that promote in rapid release, as appropriate.

In one embodiment, the e characteristics of the nutritional or pharmaceutically active agent are substantially maintained throughout the stable period.

In one embodiment, the chewable formulation delivers the nutritional or pharmaceutically active agent at substantially the same dose and rate throughout the shelf stable period.

Without wishing to be bound by theory, the applicant believes that in certain embodiments, there is no cross linking and/or polymerisation between the nutritional or pharmaceutically active agent and/or excipients or other ingredients in the formulation.

Such cross-linking and/or risation reduced the amount of nutritional or pharmaceutically active agent made available to the animal.

The chewable formulation is for ng an animal in need thereof. The suitability of the formulation for treating a ular disease or condition, for example, depends on the nutritional or pharmaceutically active agent(s) present in the formulation.

The term "treatment", and related terms, such as "treating" and "treat" as used herein, relates generally to treatment, of either a human or a non-human animal, in which some desired therapeutic effect is achieved. The therapeutic effect may, for example, be the tion of progress of a e or condition, including a reduction in the rate of progress, a halt in the rate of progress, amelioration, and cure. Treatment as a prophylactic measure is also included. Treatment also includes combination treatments and therapies, in which two or more ents or therapies are used, for example, sequentially or simultaneously, in combination.

The present invention provides use of a chewable formulation of the present invention for treating an animal in need thereof.

The present invention also provides a method of treating an animal in need thereof, comprising administering chewable formulation of the present invention.

The t invention also provides use of a ition as described herein in the cture of a chewable formulation of the present ion for treating an animal in need thereof.

The animal to be treated may be human or non-human. Non-human animals include, for example, production animals, such as, , sheep, swine, deer, and goats; companion animals, such as, dogs, cats, and horses; zoo animals, such as, zebras, elephants, giraffes, and large cats; research animals, such as, mice, rats, rabbits, and guinea pigs; fur-bearing animals, such as, mink; birds, such as, hes, emus, hens, geese, turkeys, and ducks.

A person skilled in the art will be able to readily determine the appropriate dosage of administration for treating an animal. The dosage will depend upon the nutritional or pharmaceutically active agent(s) present in the formulation and may also depend on the frequency of administration, the sex, age, weight and general condition of the animal d, the nature and severity of the condition treated, any concomitant es to be treated, and any other factors evident to those d in the art.

Although the t invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined in the appended claims.

The present invention will be further illustrated in the following Examples which are given for illustration purposes only and are not intended to limit the invention in any way.

EXAMPLES EXAMPLE 1–DISSOLUTION OF CARPROFEN The ution of carprofen in four formulations (F1–4) was tested. The formulations are shown in Table 2 below. Formulations F1 and F2 were prepared by extruding the chew twice. Formulations F3 and F4 were prepared by extruding the chew once.

Table 2. Formulations F1–4 No. Ingredient Formulations (% w/w) F1 F2 F3 F4 1 Carprofen 3.2 3.2 3.2 3.2 2 Ascorbyl ate 0.2 0.2 0.2 0.2 3 Decanox (tocopherol) 0.1 0.1 0.1 0.1 4 Arbocel M80 (cellulose powder) 14.5 15 13 13 Avicel DG (microcrystalline cellulose 5 5 5 5 75% w/w and dibasic calcium phosphate 25% w/w) 6 Methocel A15 Premium 7 7 7 7 (methylcellulose) 8 Beef Type Flavour 5 10 10 10 9 Icing Sugar 20 19 19 19 Sodium chloride - 2 2 2 11 ol ATO5 (glycerol distearate) 8 7.5 7.5 7.5 12 Glycerine able) 16 11 10 11 13 ene Glycol 11 12.5 12 12 14 Pregelatinized maize starch 10 7.5 6 5 Sodium Starch Glycollate - 16 Ac-Di-Sol (croscarmellose sodium) - - - 5 Total 100 100 100 100 Dissolution testing was carried out using 0.5 M phosphate buffer at 37C as the dissolution medium with a paddle Speed of 75.0 rpm. The dissolution apparatus used was USP Apparatus II without disk or sinker. 1. Formulations 1.1 Formulations 1 and 2 Three chewable treats were picked randomly from formulation 1 and 2 (F1 and F2) and dissolution of carprofen was tested. The results are shown in Table 3 and Table 4.

Table 3. Dissolution of carprofen from F1.

Carprofen Released (% w/w) Sample Name 0 mins 30 mins 60 mins 90 mins 120 mins 1 0.0 14.3 27.7 44.5 58.3 2 0.0 35.0 62.2 82.7 92.2 3 0.0 38.8 66.6 83.7 91.0 Avg: 0.0 29.4 52.2 70.3 80.5 Std dev: 0.0 13.2 21.3 22.3 19.2 Table 4. Dissolution of carprofen from F2.

Carprofen Released (% w/w) Sample Name 0 mins 30 mins 60 mins 120 mins 1 0.0 45.0 70.5 95.3 2 0.0 47.8 75.9 97.5 3 0.0 13.0 21.8 42.0 Avg: 0.0 35.2 56.0 78.3 Std dev: 0.0 19.4 29.8 31.4 1.2 ations 3 and 4 Three chewable treats were selected from the start, middle and end of the extrusion line and tested. Dissolution time of chewable treats obtained from the end of the extrusion line was slightly higher than that of chewable treats obtained from the start of the extrusion line. Table 5 summarizes dissolution data for F3 and Table 6 summarizes dissolution data for F4.

Table 5. Dissolution of carprofen from F3 fen Released (% w/w) Sample Name 0 mins 30 mins 60 mins 120 mins 1 0.0 60.6 88.4 97.4 2 0.0 59.6 90.5 95.3 3 0.0 49.6 79.3 95.1 Avg: 0.0 56.6 86.1 95.9 Std dev: 0.0 6.1 6.0 1.3 Table 6. Dissolution of carprofen from F4 Carprofen Released (% w/w) Sample Name 0 mins 30 mins 60 mins 120 mins start 0.0 77.8 99.5 100.8 middle 0.0 70.2 94.6 98.8 end 0.0 60.8 90.7 101.7 Avg: 0.0 69.6 94.9 100.4 Std dev: 0.0 8.5 4.4 1.5 2. Conclusion We found that the dissolution of API from chewable treats decreases as the number of extrusions performed increases. More than 80% of the API was found to be ed in the first 90 minutes.

Super disintegrants (croscarmellose sodium and sodium starch glycollate) can further improve dissolution and show up to 100% drug release in the first 90 minutes.

EXAMPLE 2–DRUG-EXCIPIENT COMPATIBILITY STUDIES IN DOG CHEWABLE TREATS CONTAINING CAM 1. Experimental design Drug-excipient compatibility studies were undertaken for meloxicamcontaining le treats.

A series of formulations were prepared by sequentially subtracting one ingredient from each formulation, as outlined in Table 7. All formulations were ed manually before storage.

Table 7. Meloxicam chewable treats prepared for compatibility studies.

Ingredients MLX-1 MLX-2 MLX-3 MLX-4 MLX-5 MLX-6 Meloxicam 0.073 0.073 0.073 0.073 0.073 0.073 Nutrisoy grits 25 25 25 25 25 Icing Sugar 23 23 23 23 23 Arbocel M80 lose powder) 16.627 41.627 20.627 16.627 16.627 39.627 Pregelatinized Starch 5 5 5 5 5 5 Salt 1 1 1 1 1 1 Beef (flavour) 4 4 4 4 4 Propylene Glycol 9 9 9 9 17 9 Glycerogelatin (10%) 8 8 8 8 8 Shortening 8 8 8 8 8 Ascorbyl palmitate 0.2 0.2 0.2 0.2 0.2 0.2 a-tocopherol 0.1 0.1 0.1 0.1 0.1 0.1 Glycerine 8 Total 100 100 100 100 100 100 1.1 Storage Conditions All the formulations were stored for 1 month at 50°C and for 6 months at 40°C. 2. s 2.1 Appearance At each time interval, the colour the meloxicam chewable treats had substantially darkened. Closer inspection revealed that this was due to darkening (or perhaps "toasting") of nutrisoy grits at elevated temperatures. Some darkening could also have been due to the beef flavouring. 2.2 cam Content The results of meloxicam assay during the compatibility study are listed in Table 8. These s clearly show that formulations MLX-2 (no nutrisoy grits) and MLX- (no shortening fat) were vely more stable that the rest of the formulations.

Degradation of Meloxicam was, thus, attributed to nutrisoy grits and shortening fat, respectively.

Table 8. Percentage of meloxicam recovered from chewable treats after 6 months at 40°C.

Sample cam (% initial) % ence Name 0 Month 1 Month 3 Months 6 Months 0-6 Months MLX-1 100.00 94.56 95.54 88.15 11.85 MLX-2 100.00 97.32 99.44 94.35 5.65 MLX-3 100.00 94.32 93.49 88.78 11.22 MLX-4 100.00 95.35 107.33 89.99 10.01 MLX-5 100.00 96.41 101.38 94.62 5.38 MLX-6 100.00 93.74 101.73 87.08 12.92 2.3 pH A slight decrease in pH was observed in all formulations, except MLX-4 (no gelatin) and MLX-5 (no shortening fat) as shown in Table 9.

Table 9. pH of meloxicam chewable treats after 6 months at 40 °C Sample pH % Difference Name 0 Month 1 Month 3 Months 6 Months 0-6 Months MLX-1 5.94 6.0 5.9 5.9 -0.78 MLX-2 5.03 5.0 5.0 5.0 -1.43 MLX-3 6.23 6.3 6.2 6.1 -2.42 MLX-4 5.92 6.1 NT* 0.15 MLX-5 5.86 6.1 6.0 6.06 3.35 MLX-6 5.65 6.0 5.9 NT* - NT*- Not tested due to icient sample EXAMPLE 3–DRUG-EXCIPIENT COMPATIBILITY STUDIES IN CHEWABLE TREATS CONTAINING CARPROFEN 1. Experimental design A series of formulations were prepared by sequentially subtracting one ingredient from each formulation, as outlined in Table 10. All formulations were extruded manually before storage.

Table 10. Carprofen chewable treats prepared for ibility studies.

Carprofen Dog Chews Ingredients CAR-1 CAR-2 CAR-3 CAR-4 CAR-5 CAR-6 Carprofen 3.2 3.2 3.2 3.2 3.2 3.2 Nutrisoy grits 25 25 25 25 25 Icing Sugar 23 23 23 23 23 Arbocel M80 (cellulose powder) 13.5 38.5 17.5 13.5 13.5 36.5 atinized Starch 5 5 5 5 5 5 Salt 1 1 1 1 1 1 Beef (flavour) 4 4 4 4 4 Propylene Glycol 9 9 9 9 17 9 Glycerogelatin (10%) 8 8 8 8 8 Shortening Fat 8 8 8 8 8 yl palmitate 0.2 0.2 0.2 0.2 0.2 0.2 a-tocopherol 0.1 0.1 0.1 0.1 0.1 0.1 Glycerine 8 Total 100 100 100 100 100 100 1.1 Storage Conditions All the ations were stored for 1 month at 50°C and for 6 months at 40°C. 2. Results 2.1 Appearance At each time interval, the colour of the carprofen chewable treats had substantially darkened. Closer inspection revealed that this was due to darkening (or perhaps "toasting") of nutrisoy-grits at elevated temperatures. Some darkening could also have been due to the beef flavouring. 2.2 Carprofen Content The results of carprofen assay during the compatibility study are listed in Table 11. These results clearly show that formulation CAR-2 (no nutrisoy grits) is the most stable formulation. The formulation CAR-5 (no ning fat) was found to be relatively more stable than the other formulations for the first three months, after which a decrease in its stability was observed. Degradation of fen was, thus, attributed to nutrisoy grits, and to a lesser extent to shortening fat.

Table 11. Percentage of carprofen recovered from chewable treats after 6 months at 40 °C.

Sample Carprofen (%initial) % Difference Name 0 Month 1 Month 3 Months 6 Months 0-6 Months CAR-1 100.00 98.75 95.81 97.15 2.85% CAR-2 100.00 98.64 98.14 98.86 1.14% CAR-3 100.00 96.62 96.89 95.97 4.03% CAR-4 100.00 96.68 95.93 95.38 4.62% CAR-5 100.00 97.87 97.94 95.42 4.58% CAR-6 100.00 96.43 96.63 95.89 4.11% 2.3 pH The st pH drop was observed in CAR-2 (no nutrisoy grits), which was also the most stable ation in terms of carprofen recovery. Interestingly, a sample of CAR-2 stored at room temperature for three months did not show any pH drop indicating that the pH decreased only at elevated temperature. A slight decrease in pH was observed in all other formulations, except CAR-5 (no shortening Fat) as shown in Table 12.

Table 12. pH of carprofen chewable treats after 6 months at 40 °C.

Sample pH % Difference Name 0 Month 1 Month 3 Months 6 Months 0-6 Months CAR-1 5.76 5.66 5.63 5.72 -0.75 CAR-2 4.96 4.29 4.36 4.32 -12.83 CAR-3 6.03 5.88 5.75 5.53 -8.29 CAR-4 5.68 5.67 5.66 5.54 -2.38 CAR-5 5.63 5.72 5.69 5.70 1.30 CAR-6 5.73 5.61 5.58 5.61 -2.09 2.4 re Content The moisture content of all the formulations had increased after storage for six months at 40°C. The greatest increase was observed in the re content of CAR- 4 (no gelatin) and CAR-5 (no shortening fat), indicating that gelatin and shortening limit moisture absorption into the chewable treats. The least increase in moisture content was observed in case of MLX-2 (no nutrisoy grits) and MLX-3 (beef flavour), indicating that nutrisoy grits and beef r tend to absorb atmospheric moisture.

Table 13. Moisture content (% w/w) of carprofen chewable treats after storage for 6 month at 40°C.

Sample Moisture content (% w/w) % Difference Name 0 Month 3 Months 6 Months (0-6 Months) MLX-1 4.97 5.36 5.62 13.03 MLX-2 5.22 5.33 5.47 4.69 MLX-3 5.24 5.65 5.54 5.72 MLX-4 4.58 5.36 5.62 22.70 MLX-5 4.96 6.20 6.16 24.03 MLX-6 5.89 6.51 NT* - NT*- Not tested due to insufficient sample E 4–CARPROFEN AND MELOXICAM CONTAINING LE TREAT 1. Experimental design Chewable treats containing carprofen (3.2% w/w) and Meloxicam (0.073% w/w) were studied to examine the stability of the treat over a period of six months.

Three formulation batches of chewable treats were prepared.

 F1: Carprofen chewable treats containing 5% beef type flavour  F2: Carprofen le treats containing 10% beef type flavour  F3: Meloxicam chewable treats containing 10% beef type flavour.

Table 14. Formulation of F1-3 Formulae (% w/w) No. Ingredient Function F01 F02 F03 1 Carprofen API 3.2 3.2 - 2 Meloxicam API - - 0.073 3 Ascorbyl Palmitate Antioxidant 0.2 0.2 0.2 4 Decanox (tocopherol) Antioxidant 0.1 0.1 - Arbocel M80 (cellulose Diluent 14.5 15 15 powder) Avicel DG crystalline Binder 5 5 6.227 cellulose 75% w/w and dibasic calcium phosphate 6 25% w/w) el A15 Premium Binder 7 7 7 8 (methylcellulose) 9 Beef Type Flavour r 5 10 10 Icing Sugar Sweetener 20 19 20 11 Sodium chloride Humectant - 2 2 Precirol ATO5 (glyceryl Lubricant 8 7.5 7.5 12 distearate) 13 Glycerine (vegetable) Humectant 16 11 11 14 Propylene Glycol Humectant 11 12.5 12 Pregelatinized maize starch Disintegrant 10 7.5 0 Total 100 100 100 The formulations were manufactured by the following method.

Carprofen or Meloxicam, Ascorbyl palmitate, Decanox, Arbocel M80, Avicel DG, Methocel A15 Premium, Beef Type r, Icing Sugar, Sodium Chloride and Precirol ATO5 were blended together by dry ng in a planetary mixer.

After dry blending was te, Glycerine and Propylene Glycol were added to the dry powder blend and the resultant mixture mixed in a ary mixer until there are no lumps.

Pregelatinized Maize Starch was then added and the resultant mixture further blended.

The resultant mixture was then added to a Single Screw Extruder and extruded at about 46 rpm.

The amount of F1 and F2 ctured was 500 g. The amount of F3 manufactured was 700 g. 1. Chemical stability 1.1 F1 (carprofen chewable treats containing 5% flavour) F1 was stored in blister packs and foil packs at 40 C and RT, respectively.

The s of six month stability s are summarized in Table 15.

Table 15. Carprofen content in F1 over 6 months.

Storage % w/w Carprofen (% initial) Condition 0 months 1 month 2 month 3 month 6 month Room Temp 3.10 3.05 3.16 3.07 3.05 (foil pack) (100.0%) (98.4%) (101.8%) (99.0%) (98.2%) 40C 3.10 3.11 3.15 3.03 3.07 (foil pack) (100.0%) (100.4%) (101.7%) (97.8%) ) Room Temp 3.10 NT NT 3.064 3.06 (blister pack) (100.0%) (98.8%) (98.7%) 40C 3.10 NT NT 3.12 2.92 (Blister pack) (100.0%) (100.5%) (94.1%) NT: Not Tested As shown in Table 15 at 6 months there was very little ation of carprofen in each of the foil packs and in the blister pack at RT. The percentage of carprofen reduced by 5.9% in the blister pack stored at 40C. 1.2 F2 (carprofen chews containing 10% flavour) F2 was stored in foil packs at 50 C, 40 C and RT. The results of six month stability studies are summarized in Table 16.

Table 16. Carprofen content in F2 over 6 months.

Storage % w/w Carprofen (% l) Condition 0 months 1 month 2 month 3month 6month Room Temp 3.15 3.08 3.15 3.04 3.03 (foil pack) (100.0%) (97.8%) (100.0%) (96.6%) (96.2%) 40C 3.15 3.05 3.14 3.01 3.05 (foil pack) (100.0%) ) (99.8%) (95.4%) (96.6%) 50C 3.15 3.05 3.14 2.96 NT (foil pack) (100.0%) (96.7%) (99.6%) (93.8%) NT: Not Tested 1.3 F3 (meloxicam chews containing 10% flavour) F3 was stored in foil packs at 50C, 40C and RT, respectively. The results of h stability studies are summarized in Table 17.

Table 17. Meloxicam t in F3 over 6 months.

Storage % w/w Meloxicam (% initial) Condition 0 months 1 month 2 month 3month 6month Room Temp 0.0690 0.0686 0.0683 0.0677 0.0671 (foil pack) (100.0%) (99.4%) (99.0) (98.1%) (97.2%) 40C 0.0690 0.0685 0.0669 0.0664 0.0669 (foil pack) (100.0%) (99.3%) ) (96.2%) (97.0%) 50C 0.0690 0.0666 0.0675 0.0654 NT (foil pack) (100.0%) (96.5%) (97.8%) (94.8%) NT: Not Tested 2. al stability 2.1 Appearance Significant darkening of F1–3 chews was observed at 40C and 50C, with the dark colour being more intense at the surface of the chew and in the interior. No significant colour change was observed in F1–3 chews stored at room temperature. 2.2 Moisture content Moisture content of the chews was analysed by Karl Fisher Titration .

Small changes in the moisture content (% w/w) of F1–3 were observed during six month e as summarized in Table 18.

Table 18. Moisture content of F1–3 over 6 months.

Sample Package Moisture content (% w/w) Name 0 1 2 3 6 months months months months months F1-RT Foil pack 8.2 4.1 4.7 5.9 6.5 F1–40C Foil pack 8.2 4.7 4.6 5.0 5.5 F1-RT Blister pack 8.2 NT NT 8.1 6.1 F1–40C Blister pack 8.2 NT NT 5.6 8.7 F2–RT Foil pack 3.5 5.3 4.2 4.9 6.6 F2–40C Foil pack 3.5 4.8 4.7 6.3 4.8 C Foil pack 3.5 3.2 5.0 5.1 NT F3–RT Foil pack 5.5 6.7 5.1 5.0 4.5 F3–40C Foil pack 5.5 5.4 5.3 4.7 4.8 F3–50C Foil pack 5.5 5.9 5.9 5.0 NT NT: Not Tested It is thought that the high initial moisture content of F1 could be due to time lag (12 days) between pulverization and analysis of the chews (which was avoided hereafter). 2.3 pH Minimal s in pH of F1-3 were observed during six month storage as summarized in Table 19.

Table 19. pH of F1-3 over 6 months.

Sample Package pH Name 0 1 2 3 6 months months months months months F1-RT Foil pack 5.1 5.1 5.2 5.3 5.3 F1–40C Foil pack 5.1 4.9 5.0 5.0 4.8 F1-RT Blister pack 5.1 NT NT 5.2 5.3 F1–40C Blister pack 5.1 NT NT 5.0 4.8 F2–RT Foil pack 5.0 5.0 5.0 5.0 4.9 F2–40C Foil pack 5.0 4.9 4.9 4.8 4.9 F2–50C Foil pack 5.0 4.9 4.9 4.9 NT F3–RT Foil pack 5.3 5.4 5.3 5.2 5.4 F3–40C Foil pack 5.3 5.3 5.3 5.1 5.4 F3–50C Foil pack 5.3 5.2 5.3 5.2 NT 2.4 iological stability Microbiological evaluation was done for F1 after six months at room temperature and for F2 after six months at room temperature and 40C, respectively.

The results of microbiological assay are summarized in Table 20.

Table 20. Microbiological g in F1 and F2.

Sample Stability Package Microbilogical Testing Name Time point TAMC TYMC Pathogens* F1–RT 6 months Foil pack <10 cfu/g <10 cfu/g None detected C 6 months Foil pack <10 cfu/g <10 cfu/g None detected F2–RT 6 months Blister pack <10 cfu/g <10 cfu/g None detected * Pathogens tested: E.coli, S.aurens, P.aeruginosa, Salmonella F1–3 are stable over the tested period.

Based on the stability trials, xcipient compatibility studies and extrusion trials, semi-soft chewable treats comprising carprofen and meloxicam were ated as follows.

 Water was not added to the chew formulation at any time during manufacture.

 Guar gum was replaced with higher concentration of strong dry binding agents, Methocel (methylcellulose) and Avicel (75% microcrystalline cellulose + 25% dibasic calcium phosphate), to improve rigidity and strength of the chews.

 The amount of Nutrisoy grits was decreased or Nutrisoy was .

 Povidones were removed due to trace peroxide impurities in them. They were tuted with other disintegrants, such as pregelatinized maize starch, croscarmellose sodium and sodium starch glycollate.

 Ascorbyl ate was used as antioxidant, since this was a powder better distribution in the powder blend was expected. Tocopherols were used for synergistic effect with Ascorbyl palmitate.

 Shortening fat was replaced with other fats/lipids that melt between 40- 90C. Glyceryl distearate NF/ glycerol distearate (Type I) EP, having a melting point n C was used in a formulation. Several other fats, such as glycerol monostearate (melting point: 54-64C), behenoyl polyoxylglycerides NF (drop point: 60-74C ), hydrogenated coconut oil or hard fat (melting point: 42-44C ) were also tried.  se sugar replaced with a non-reducing sugar (sucrose) to avoid their Maillard reaction.

The chews manufactured in this manner had the following benefits.

 Rigid, but chewy. Do not get deformed easily, 0% or very low friability  Do not harden or become e over time.

 Easy to manufacture.

 Good chemical stability of active ingredients.

 No microbial contamination.

 Dissolution rapid compared to other products in market (Drontal, Heartgard).

EXAMPLE 5–SIX MONTHS PRELIMINARY STABILITY REPORT FOR MELOXICAM This example describes a six month stability trial for three batches of meloxicam-containing dog le treats. 2.5 Experimental design Three small-scale batches, 1.5 kg each, of meloxicam-containing dog chewable treats were manufactured.

Each of the three batches represents a different formulation. All the chews from each batch were packed in ealed aluminium foil bags and stored at three stability conditions for 12 . 2.6 Formulation Details Three batches, B1, B2 and B3, of meloxicam-containing dog chewable treats were prepared. Formulation details of each batch are shown in Table 21. All quantities are shown in % w/w.

Table 21. Formulation s for three batches of Meloxicam Dog Chewable Treat.

Batch Number B1 B2 B3 Meloxicam 0.073 0.073 cam-PEG6000(1:3) Granules 0.292 Guar Gum 0.25 0.25 0.25 Beef Flavour 3.00 3.00 3.00 Salt 2.00 2.00 2.00 Polyplasdone XL (crospovidone) 5.00 5.00 5.00 Arbocel M80 (cellulose powder) 7.00 7.00 7.00 NutrisoyGrits 40/20 25.00 25.00 25.00 DextroseMonohydrate USP (QS) 18.18 24.58 24.36 Water 10.00 Glycerol 13.00 13.00 13.00 Propylene Glycol 6.40 10.00 10.00 Decanox (tocopherol) 0.10 0.10 0.10 Shortening fat 10.00 10.00 10.00 Total 100.00 100.00 100.00 2.7 e Conditions and Tests Stability samples were tested against the stability specification AR-STS- 0014, Issue-1. The storage conditions and time points for ity tests are represented in Table 22.

Table 22. Storage conditions and time points for the preliminary stability test for Meloxicam Dog Chewable .

Storage Test intervals (months) conditions 0 1 2 3 6 9 12 Spares Room X* X* X* X* X X X temperature C/65% X* X* X* X X X X 40C/65% X X X X X X X A l testing (T=0): Full testing as per AR-STS-0014 (23 chews required).

X* Physical testing only as per -0014: pH, moisture, disintegration and appearance (5 chews required).

X Full testing as per AR-STS-0014 except uniformity of content is not required (13 chews required).

Spares are placed at room conditions, 30C/65% RH and 40C/75% RH. 3. Results The summary of test results are shown in Table 23 below.

Table 23. Summary of test results 3.1 Organoleptic properties There was a significant change in the colour and appearance of the cam-containing dog chewable treats. The colour of the chews grew darker with time and temperature. There was no change in the odour at any storage condition. 3.2 pH There was a significant decrease in the pH of the meloxicam-containing dog chewable treats over a period of 6 months. The difference in pH was greater for B2 and B3 than for B1. 3.3 Disintegration time There was significant change in the disintegration time of all three batches.

Disintegration time for B1 increased with ature, whereas, the disintegration time of B2 and B3 decreased after storage at higher temperature.

The disintegration time for B2 and B3 after storage at any temperature was less than the corresponding disintegration time for B1. 3.4 % Moisture content There was an l increase in the moisture content of all the three batches of dog chews. Maximum change was observed in s stored at 40C/75% RH. The difference in moisture content was found to be more in B2 and B3 as compared to B1. 3.5 cam content Meloxicam content was found to decrease linearly with time. After storage for six months at 30C/65% RH and 5% RH it had dropped to less than the specification limit of 90% w/w. 3.6 Uniformity of content Uniformity of content of meloxicam in meloxicam-containing dog chewable treats was tested only at the time of release and was found to be within acceptable 3.7 Physical nature The chewable treats had not dried out and retained their soft pliable nature.

The chewable treats are subjected to a hardness measurement that measures the deformability of the chewable treat. A measurement lower than that for chewable treats manufactured with water demonstrates that manufacture with the absence of free water (i.e. added water) allows the chewable treat to retain its deformability compared to a chewable treat manufactured with added water. Chewable treats manufacture with water become brittle which s their dissolution rate and drug stability. 4. Conclusions Meloxicam t dropped below 90% w/w for all three batches of meloxicam-containing dog chewable treats, when tested after six month storage at C/65% RH and 40C/75% RH. This may be due to the presence of NutriSoyGrits 40/20, which e 2 suggests has a detrimental effect on the stability of meloxicam.

The ce of water in formulation B1 may also have a detrimental effect on the stability of meloxicam. Also, there was a significant change observed in appearance, disintegration time and moisture content of all three batches, at all storage conditions.

EXAMPLE 6–WATER ACTIVITY The water activity of two chewable ations was tested. One of the ations was a o containing no pharmaceutically active agent and the other contained meloxicam. The method used was AOAC 978.18. The results are shown in Table 24 below.

Table 24. Water activity of chewable formulations.

Formulation Description Water activity F6 6 month old placebo chewable formulation 0.335 F3 23 month old meloxicam chewable formulation 0.292 Both formulations had low water activity.

Details of the ingredients of F3 and F6 are provided in Table 25 below. All quantities are shown in % w/w.

Table 25. Ingredients of F3 and F6.

Ingredient F3 F6 Meloxicam 0.073 - Ascorbyl Palmitate 0.2 0.2 Cellulose Powder 15 13 Avicel DG crystalline 6.127 6.5 Cellulose 75% w/w and Dibasic Calcium Carbonate % w/w) Methylcellulose 7 7 Beef type flavour 10 - Vanilla flavour - 1 Caramel colour - 0.3 Confectioner’s Sugar 20 20 Sodium chloride 2 - Glyceryl Distearate 7.5 8 Glycerine (vegetable) 11 14 Propylene Glycol 12 15 Pregelatinized starch 9 10 Croscarmellose sodium - 5 Total 100.00 100.00 At the date of testing F3 was 23 months old and F6 was 6 months old. The data shows that a low water activity can be maintained in the chewable ations over an extended period of time.

EXAMPLE 7–TEXTURE PROFILE ANALYSIS The texture profile of five chewable formulations (F1, F3, F7, F8, and F9) was analysed. 1. ations The formulations were in the form of cylindrical extrudates having a diameter of 15mm and a height n 14 and 16mm.

Details of each the ingredients of each formulation are provided below in Table 26.

F1, F3, and F9 contained fen, meloxicam and metoclopramide, respectively. F7 and F8 were were placebos containing no pharmaceutically active agent.

At the date of g, F1 was 24 months old, F3 was 23 months old, F7 and F8 were 6 months old and F9 was 2 months old.

Table 26. Ingredients of formulations.

Ingredient F1 F3 F7 F8 F9 Meloxicam - 0.073 - - - Carprofen 3.2 - - - - Metoclopramide - - - - 0.3 Ascorbyl Palmitate 0.2 0.2 0.2 0.2 0.2 Tocopherols 0.1 - - - - Arobcel M80 (Cellulose 14.5 15 13 12.8 12.5 Powder) Avicel DG (Microcrystalline Cellulose 75% w/w and 6127 6.5 5 5 Dibasic Calcium Carbonate % w/w) Methylcellulose 7 7 7 7 7 cal beef flavour 5 10 - - 5 Butter caramel flavour - - Roast pork flavour - - Chicken fat concentrate - - - 0.5 - Stewed beef flavour - - - - 0.5 Caramel colour - - 0.3 - - Confectioner’s Sugar 20 20 20 20 20 Sodium chloride - - Glyceryl Distearate 8 7.5 8 8 8 Glycerine (vegetable) 16 11 14 13 13 Propylene Glycol 11 12 15 13.5 13.5 Pregelatinized starch 10 9 10 10 10 Croscarmellose sodium - - 5 5 5 Total 100.00 100.00 100.00 100.00 100.00 2. e profile analysis Texture profile is is a e measurement that simulates two ‘bites’ by compressing a food sample twice between a base and a plate at constant speed and measuring the force versus time. The test is widely used in food research. 2.1 Test ure A single cylindrical extrudate having a diameter of 15mm and a height between 14 and 16mm of each formulation was tested using an Instron 4444 texture analyser instrument. A double 9mm ssion was carried out on each tablet with a 65mm diameter aluminium plate, at a crosshead speed of 100mm/min. All tests were carried out at room temperature (25±1°C). 2.2 Results The results of the texture profile analysis are shown below in Tables 27 and Table 27. Compression.

Formulation Height (mm) Compression Actual Compression Target (mm) Compression (%) * (mm) F1 15.1 9 8.8 58 F3 15.7 9 8.7 56 F7 14.8 9 8.6 58 F8 14.0 9 8.2 58 F9 16.1 9 8.8 55 * Actual ssion is dependent on the shape of the sample tested.

A comparable degree of compression was achieved with all tablets tested.

Table 27. e profile is. n N) n m) ti o ( io ess s ( ss ss N. m ( n n si o ul a ne re gi n es in s lu m) si o m) rm gy ) du Fo rd Ha Co mp er En he .m he Co Sp ri n ew Ad (N (% Ch Mo (N /m F1 180 897 -2.94 0.082 15 2.26 34.9 F3 267 1432 -6.14 0.081 18 3.90 53.2 F7 162 740 -0.49 0.088 19 2.78 28.9 F8 231 912 -2.55 0.089 19 3.93 34.4 F9 154 819 -2.61 0.086 19 2.57 31.4 The results are generally similar for all of the formulations tested. This suggests that texture of the formulation does not change significantly on storage.

Notably, all of the samples tested yielded, rather than fractured in the first bite.

A double compression curve for F8 is shown in Figure 2. The curve is typical for the formulations tested.

A description of the properties of the formulations in Table 27 above and how the properties were evaluated is provided in Table 28 below.

Table 28. Description of properties evaluated.

Property Definition or calculation Fracture (N) The first peak in the force curve. Also called brittleness. Not observed in any of the samples .

Hardness (N) The force at maximum compression.

Compression Area under the force-deformation curve for the first bite. energy (N.mm) Adhesion Area under the extension curve for the first bite. When the probe (N.mm) reverses the sample may stick and a ve force is recorded up until the sample releases.

Cohesiveness Compression energy of the second bite d by the compression (-) energy of the first bite.

Springiness (-) Ratio of the duration of contact with the sample during the second compression to that during the first compression. Springiness is a measure of the extent to which the sample recovers from the first compression. A value of 1 means total recovery, a value of 0 means no recovery (sample does not bounce back from the compression).

Chewiness (N) Product of hardness, cohesiveness and springiness.

Modulus Initial slope of the force-deformation curve. Calculated by ng (N/mm) the force at 3mm compression by 3mm.

EXAMPLE 8–INGREDIENTS OF CHEWABLE ATIONS Chewable ations having the ingredients shown in Table 29 were prepared. All of the quantities are shown in % w/w.

Table 29. Ingredients of chewable formulations. ient Classification Function Content API s Therapeutic 0.073-16.0% Total API 0.073-16.0% Ascorbyl Palmitate Fatty acid ester Antioxidant/stabilizer 0.20% BHT Phenolic Antioxidant/stabilizer Tocopherol Vit E Antioxidant/stabilizer 0.10% Buffers Various Stabilizer Total antioxidant/stabilizer 0-0.3% Croscarmellose Cellulosic Super-Disintegrant 0-25% sodium (Ac-Di-Sol) biopolymer Sodium Starch Starch Super-Disintegrant 0-5% Glycollate (SSG) Polyplasdone XL Povidone Super-Disintegrant 0-5% (crosspovidone) Pregelatinized Starch egration aid 0-10% starch Total disintegrant 0-25% Nutrisoy Grits Protein Filler 20-25% Wheat Germ Protein Filler 25% l M80 Cellulosic Filler 0-15% (cellulose powder) biopolymer Lactose Disaccharide sugar Filler 0-48% monohydrate Total filler q.s.

Avicel DG (microcrystalline Microcrystalline cellulose75% w/w cellulose and Filler/binder 0-10% and c calcium dibasic calcium phosphate 25% phosphate Methocel A15 Cellulose ether Premium Filler/binder 3-15% biopolymer (methylcellulose) Total binder 0.25-25% r (solid) tic Flavour/taste masker 3-10% Flavour (liq) Synthetic Flavour/taste masker 0.5-2% Total flavour 0-10% Icing Sugar Sugar Sweetener 0-30% Dextrose Sugar Sweetener 28.18% drate Compressible Sugar Sugar Sweetener 0-39% Total sugar 10-64% Precirol ATO5 Glycerol stearate ant (fat/lipid) 7-8% (glyceryl stearate) (mixed polymer) Shortening Fat Lipid/fat Lubricant (fat/lipid) 10% Total lubricant 7-10% Glycerine Glycerol Plasticizer/humectant 0-36%% (vegetable) Propylene Glycol Glycol Plasticizer/humectant 0-31%% Total cizer/humectant 16-36% PEG-6000 Protective coating 20% Stearic Acid tive coating 0.657% Total coating 20% Total 100% The active ingredient (API) in Table 29 above was selected from those listed in Table 30 below. All of the quantities are shown in % w/w.

Table 30. APIs in chewable formulations.

API Classification Aqueous solubility Content Carprofen NSAID Poor 3.2 Meloxicam NSAID Poor 0.073 Diphenhydramine Antihistamine Soluble 0.83 Metoclorpramide Antiemetic Soluble 0.33-2 Spinosad Parasiticide Soluble 16 Prednisolone Corticosteroid Poor 1.33 Milbemycin oxime Parasiticide Poor 0.1-3% Pyrantel Parasiticide Poor 10.56% Abamectin Parasiticide Poor 0.0073% Praziquantel Parasiticide Soluble 3.67% Oxibendazole Parasiticide Poor 16.50% Details of 45 chewable formulations (some placebo) that were prepared are provided in Table 31 below.

Table 31. Formulations of the invention.

Ingredients 1 2 3 4 API Meloxicam %) o Meloxicam (0.073%) Placebo Disintegrant Ac-Di-Sol Pre-gel Starch Other Polyplasdone XL (5%) Polyplasdone XL (5%) Polyplasdone XL (5%) Polyplasdone XL (5%) Filler / Arbocel M80 7.00% 7% 7% 4% Binder Avicel DG Binder Guar gum (0.25%) Guar gum (0.25%) Guar gum (0.25%) Guar gum (0.25%) Other Wheat germ (25%) Nutrisoy Grits (25%) Nutrisoy Grits (25%) Nutrisoy Grits (20%) Plasticizer / Glycerine 13% 13% 13% 13% ant Propylene 6.40% 10.00% 10.00% 10.00% Glycol Other Salt (2%) Salt (2%) Salt (2%) Salt (1.5%) r / Flavor Beef Powder ( 3%) Beef Powder ( 3%) Beef Powder ( 3%) Beef Powder ( 3%) Sweeteners Sugar Dextrose (28.18%) Dextrose (24.65%) Dextrose (24.58%) Dextrose (13.15%) / Colour Colour AntiOx / Ascorbyl Decanox (0.1%) Decanox (0.1%) Decanox (0.1%) Decanox (0.1%) Stabilizers Palmitate Other Lubricant ning (10%) Shortening (10%) Shortening (10%) Shortening (10%) PEG6000 (20%) Total liquid 19.40% 23.00% 23.00% 23.00% Ingredients 5 6 7 8 API Placebo Meloxicam (0.073%) Meloxicam (0.073%) cam (0.073%) Disintegrant Ac-Di-Sol Pre-gel Starch Other Polyplasdone XL (5%) Polyplasdone XL (5%) Polyplasdone XL (5%) Polyplasdone XL (5%) Filler / Arbocel M80 4% 7% 7% 7% Binder Avicel DG Binder Guar gum (0.25%) Guar gum (0.25%) Guar gum ) Guar gum (0.25%) Other Nutrisoy Grits (25%) Nutrisoy Grits (25%) Nutrisoy Grits (25%) Nutrisoy Grits (25%) cizer / Glycerine 13% 13% 13% 13% Humectant Propylene 8% 10% 10% 10% Glycol Other Salt (1.5%) Salt (2%) Salt (2%) Salt (2%) Flavour / Flavor Beef Powder ( 3%) Beef Powder ( 3%) Beef Powder ( 3%) Beef Powder ( 3%) Sweeteners Sugar Dextrose %) Dextrose (24.36%) Dextrose (23.92%) Dextrose (23.92%) / Colour Colour AntiOx / Ascorbyl Decanox (0.1%) Decanox (0.1%) Decanox (0.1%) Decanox (0.1%) Stabilizers Palmitate Other Lubricant Shortening (10%) Shortening (10%) Shortening (10%) Shortening (10%) PEG6000 (20%) 0 (0.219%) PEG6000 (0.657%) Stearic acid (0.657%) Total liquid 21.00% 23.00% 23.00% 23.00% Ingredients 9 10 11 12 API Carprofen (3.2%) Carprofen (3.2%) Carprofen (3.2%) Meloxicam (0.073%) Disintegrant Ac-Di-Sol Pre-gel 10% 5% 7.50% 9% Starch Other Filler / Arbocel M80 14.5 14.5 15% 15% Binder Avicel DG 5% 5% 5% 6.13% Binder Methocel (7%) Methocel (7%) Methocel (7%) Methocel (7%) Other Plasticizer / Glycerine 16% 16% 11% 11% Humectant Propylene 11% 11% 12.50% 12% Glycol Other Salt (2%) Salt (2%) r / Flavor Beef Powder (5%) Beef Powder (10%) Beef Powder (10%) Beef Powder (10%) Sweeteners Sugar ICS (20%) ICS (20%) ICS (19%) ICS (20%) / Colour Colour AntiOx / Ascorbyl Ascorbyl Ascorbyl yl Ascorbyl Stabilizers Palmitate palmitate(0.2%) palmitate(0.2%) palmitate(0.2%) ate(0.2%) Other Decanox (0.1%) x (0.1%) Decanox (0.1%) Decanox (0.1%) Lubricant Precirol AT05 (8%) Precirol AT05 (8%) Precirol AT05 (7.5%) Precirol AT05 (7.5%) Total liquid 27.00% 27.00% 23.50% 23.00% Ingredients 13 14 15 16 API Carprofen (3.2%) Carprofen (3.2%) Placebo Placebo Disintegrant Ac-Di-Sol 5% 5% 5% Pre-gel 6% 5% 10% 10% Starch Other SSG( 5%) Filler / Arbocel M80 13% 13% 13% 12.80% Binder Avicel DG 5% 5% 6% 5% Binder Methocel (7%) Methocel (7%) Methocel (7%) el (7%) Other Plasticizer / ine 10% 11% 12% 13% ant Propylene 12% 12% 12% 14% Glycol Other Salt (2%) Salt (2%) Salt (2%) Flavour / Flavor Beef Powder (10%) Beef Powder (10%) Beef liq (0.5%) Beef Powder (5%) Sweeteners Sugar ICS (19%) ICS (19%) lactose (23.8%) ICS (20%) / Colour Colour AntiOx / Ascorbyl Ascorbyl Ascorbyl Ascorbyl Ascorbyl Stabilizers Palmitate palmitate(0.2%) palmitate(0.2%) palmitate(0.2%) palmitate(0.2%) Other Decanox (0.1%) Decanox (0.1%) Lubricant Precirol AT05 (7.5%) Precirol AT05 (7.5%) Precirol AT05 (7.5%) Precirol AT05 (8%) Total liquid 22.00% 23.00% 24.00% 27.00% Ingredients 17 18 19 20 API o Placebo Placebo Placebo Disintegrant Ac-Di-Sol 5% 5% 5% 5% Pre-gel 10% 10% 10% 10% Starch Other Filler / Arbocel M80 12.80% 13.80% 13% 13% Binder Avicel DG 5% 6% 6.50% 6.50% Binder Methocel (7%) Methocel (7%) Methocel (7%) Methocel (7%) Other Plasticizer / Glycerine 13% 13% 14% 14% Humectant Propylene 13.50% 14% 15% 15% Glycol Other Flavour / Flavor Beef pdr +liq Butter Caramel Liq Butter Caramel Liq Vanilla liq +Vanillin Sweeteners (5%+0.5%) (1%) (1%) (1%+0.4%) / Colour Sugar ICS (20%) ICS (21%) ICS (20%) ICS (20%) Colour l (2%) Caramel (0.3%) Caramel (0.3%) AntiOx / yl Ascorbyl Ascorbyl Ascorbyl Ascorbyl izers Palmitate palmitate(0.2%) palmitate(0.2%) palmitate(0.2%) palmitate(0.2%) Other Lubricant Precirol AT05 (8%) Precirol AT05 (8%) Precirol AT05 (8%) Precirol AT05 (8%) Total liquid 26.50% 27.00% 29.00% 29.00% Ingredients 21 22 23 24 API Placebo Placebo Placebo Placebo Disintegrant Ac-Di-Sol 5% 5% 5% 5% Pre-gel 10% 10% 10% 10% Starch Other Filler / l M80 12.80% 12.80% 12.80% 12.80% Binder Avicel DG 5% 5% 5% 5% Binder Methocel (7%) Methocel (7%) Methocel (7%) Methocel (7%) Other Plasticizer / Glycerine 13% 13% 13% 13% Humectant Propylene 13.5% 13.5% 13.5% 13.5% Glycol Other Flavour / Flavor Chicken pdr+Fish liq Beef pdr +liq Pork pdr+ n liq Chicken pdr+ n Sweeteners (5%+0.5%) (5%+0.5%) (5%+0.5%) liq (5%+0.5%) / Colour Sugar ICS (20%) ICS (20%) ICS (20%) ICS (20%) Colour AntiOx / Ascorbyl yl Ascorbyl Ascorbyl Ascorbyl Stabilizers Palmitate palmitate(0.2%) palmitate(0.2%) palmitate(0.2%) palmitate(0.2%) Other Lubricant Precirol AT05 (8%) Precirol AT05 (8%) Precirol AT05 (8%) Precirol AT05 (8%) Total liquid 26.50% 26.50% 26.50% 26.50% Ingredients 25 26 27 28 API Metoclorpramide Spinosad (16%) Defenhydramine Prednisolone (1.3%) (0.3%) ) Disintegrant Ac-Di-Sol 5% 5% 5% 5% Pre-gel 10% 10% 10% Starch Other Filler / l M80 12.50% 6.80% 9.97% 10.70% Binder Avicel DG 5% 5% 7% 7% Binder Methocel (7%) Methocel (7%) Methocel (7%) Methocel (7%) Other Plasticizer / Glycerine 13% 12.50% 13% 14% Humectant Propylene 13.5% 12% 13.50% 15% Glycol Other r / Flavor Beef pdr +liq Beef pdr +liq Pork pdr+ Chicken liq Butter Caramel Liq Sweeteners (5%+0.5%) (5.5%+2%) (5%+0.5%) (1%) / Colour Sugar ICS (20%) ICS (20%) ICS (20%) ICS (21%) Colour Caramel (0.3%) AntiOx / Ascorbyl Ascorbyl Ascorbyl Ascorbyl Ascorbyl Stabilizers Palmitate palmitate(0.2%) palmitate(0.2%) palmitate(0.2%) palmitate(0.2%) Other Lubricant Precirol AT05 (8%) ol AT05 (8%) Precirol AT05 (8%) Precirol AT05 (8%) Total liquid 26.50% 24.50% 26.50% 29.00% Ingredients 29 30 31 32 API Placebo Metoclorpramide (2%) Metoclorpramide (2%) orpramide (2%) Disintegrant Ac-Di-Sol 4% 10% 5% 25% Pre-gel Starch Other Filler / Arbocel M80 0.00% 0.00% 0.00% 15.00% Binder Avicel DG 0% 2% 4% 2% Binder Methocel (4%) Methocel (3%) Methocel (6%) Methocel (3%) Other Plasticizer / Glycerine 9% 10% 10.00% 20% Humectant ene 13% 6% 6% 6% Glycol Other Flavour / Flavor Compressible Sugar Compressible Sugar Compressible Sugar Compressible Sugar Sweeteners (39%) (30%) (30%) (10%) / Colour Sugar ICS (25%) ICS (30%) ICS (30%) ICS (10%) Colour AntiOx / Ascorbyl Stabilizers ate Other Lubricant Precirol AT05 (6.5%) Precirol AT05 (7%) Precirol AT05 (7%) Precirol AT05 (7%) Total liquid 21.50% 16.00% 16.00% 26.00% Ingredients 33 34 35 36 API Metoclorpramide (2%) Metoclorpramide (2%) Metoclorpramide (2%) Carprofen (2%) Disintegrant Ac-Di-Sol 5% 25% 5% 5% Pre-gel Starch Other Filler / Arbocel M80 15.00% 2.00% Binder Avicel DG 10% 10% 2% 2% Binder Methocel (15%) Methocel (15%) Methocel (3%) Methocel (3%) Other Lactose (48%) Lactose (5%) Plasticizer / Glycerine 18% 11% 12.00% 10% ant Propylene 8% 18% 11% 6% Glycol Other r / Flavor Compressible Sugar Compressible Sugar ners (10%) (30%) / Colour Sugar ICS (10%) ICS (10%) ICS (10%) ICS (30%) Colour AntiOx / Ascorbyl Stabilizers Palmitate Other Lubricant Precirol AT05 (7%) Precirol AT05 (7%) Precirol AT05 (7%) Precirol AT05 (7%) Total liquid 26.00% 29.00% 23.00% 16.00% Ingredients 37 38 39 40 API Carprofen (2%) Carprofen (2%) Carprofen (2%) Carprofen (2%) Disintegrant Ac-Di-Sol 25% 5% 8% 25% Pre-gel Starch Other Filler / Arbocel M80 Binder Avicel DG 2% 10% 3% 10% Binder el (3%) Methocel (15%) Methocel (4.5%) el (10%) Other e (33%) Lactose (30%) Plasticizer / Glycerine 10% 10% 6% 13% Humectant Propylene 8% 11% 10% 16% Glycol Other Flavour / Flavor Compressible Sugar Sweeteners (30%) / Colour Sugar ICS (10%) ICS (10%) ICS (30%) ICS(10%) Colour AntiOx / Ascorbyl Stabilizers Palmitate Other Lubricant Precirol AT05 (7%) Precirol AT05 (7%) Precirol AT05 (7%) Precirol AT05 (7%) Total liquid 18.00% 21.00% 16.00% 29.00% Ingredients 41 42 43 44 API fen (2%) Carprofen (2%) Carprofen (2%) Carprofen (2%) Disintegrant Ac-Di-Sol 25% 25% 25% 25% Pre-gel Starch Other Filler / Arbocel M80 Binder Avicel DG 10% 10% 10% 10% Binder el (10%) Methocel (10%) Methocel (10%) Methocel (10%) Other Plasticizer / Glycerine 0% 36% 0% 25% Humectant Propylene 25% 0% 31% 0% Glycol Other Flavour / Flavor Sweeteners Sugar ICS(10%) ICS(10%) ICS(10%) ICS(10%) / Colour Colour AntiOx / Ascorbyl Stabilizers Palmitate Other Lubricant Precirol AT05 (7%) Precirol AT05 (7%) ol AT05 (7%) Precirol AT05 (7%) Total liquid 25.00% 36.00% 31.00% 25.00% Ingredients 45 API Carprofen (2%) Disintegrant Ac-Di-Sol 25% Starch Other Filler / Arbocel M80 Binder Avicel DG 10% Binder Methocel (10%) Other Plasticizer / Glycerine 25% Humectant Propylene 10% Glycol Other Flavour / Flavor Sweeteners Sugar ICS(10%) / Colour Colour AntiOx / Ascorbyl Stabilizers Palmitate Other Lubricant Precirol AT05 (7%) Total liquid 35.00% EXAMPLE 9–DISSOLUTION OF FORMULATIONS OF THE INVENTION Eight chewable formulations were prepared and their ution tested. The ure used was as described above in Example 1. The results are shown below in Table 32. All of the quantities are shown in % w/w.

Table 32. Dissolution of formulations of the invention.

API DT (mins) Dissolution of API at 15 mins F#1 Metoclorpramide 22 <75% F#2 Metoclorpramide 30 >75% F#3 Metoclorpramide 12 >75% F#4 Metoclorpramide 15 >75% F#5 Carprofen 30 <75% F#6 Carprofen 15 <75% F#7 Carprofen 18 >75% F#8 Carprofen 27 >75% Details of the ients of formulations F#1-F#8 are shown below in Table 33. All of the quantities are shown in % w/w.

Table 33. Ingredients of formulations. ient F#1 F#2 F#3 F#4 F#5 F#6 F#7 F#8 Soluble API 2% 2% 2% 2% - - - - (Metoclorpramide) Insoluble API - - - - 2% 2% 2% 2% (Carprofen) Disintegrant (Ac- 10% 5% 25% 5% 5% 25% 5% 7.5% Di-Sol) Binder (2:3) 5% 10% 25% 5% 5% 5% 25% 7.5% (Avicel DG:Methocel A15) Sweetener (Icing 30% 30% 10% 10% 30% 10% 10% 30% Sugar) Sweetener c 30% 30% - - 30% - - 30% Sugar) Diluent (Arbocel - - 2% 48% 5% 33% 30% - M80 / Lactose) Precirol ATO5 7% 7% 7% 7% 7% 7% 7% 7% Glycerine 10% 10% 11% 12% 10% 10% 10% 6% Propylene Glycol 6% 6% 18% 11% 6% 8% 11% 10% The dissolution profiles of the formulations over time are shown in Figure 3.

At 30 minutes, the dissolution of all of the ations was >75%. At 90 minutes, the dissolution of all of the formulations was 100%.

Having thus described in detail preferred ments of the present invention, it is to be understood that the invention defined by the above paragraphs is not to be limited to particular details set forth in the above description as many apparent variations f are possible without departing from the spirit or scope of the present invention.

Claims (32)

1. A shelf stable veterinary chewable formulation, comprising: a nutritional or pharmaceutically active agent, a plasticiser, and a lubricant selected from the group consisting of fats, lipids, and a combination of fats and lipids, a filler, or a sweetener, or a filler and a ner, n the formulation is formed by extrusion and the formulation has a water activity (aw) of from about 0.1 to about 0.60.

2. The chewable formulation according to claim 1, wherein the ceutically active agent is selected from anesthetics, corticosteroids, NSAIDS, antibiotics, antiemetics, anti-thyroidal agents or anti-parasiticidal agents, or any combination of any two or more f.

3. The chewable formulation according to claim 1 or 2, wherein the pharmaceutically active agent is an anthelmintic.

4. The chewable formulation according to any one of claims 1 to 3, wherein the pharmaceutically active agent is an NSAID.

5. The chewable formulation according to any one of claims 1 to 4, wherein the chewable formulation comprises  a filler, diluent or filler and diluent,  a binder,  a sweetener,  a ring agent,  a ant,  a fat, lipid or fat and lipid,  an antioxidant,  a colouring agent,  a disintegrating agent,  a preservative, ing agent, or preservative and buffering agent, or  any combination of any two or more thereof.

6. The le formulation according to any one of claims 1 to 5, comprising two or more fillers.

7. The chewable formulation according to any one of claims 1 to 6, comprising 2 to 40% by weight filler.

8. The chewable formulation according to any one of claims 1 to 7, comprising 0.1 to 15% by weight binder.

9. The chewable formulation according to any one of claims 1 to 8, comprising 5 to 30% by weight sweetener.

10. The chewable formulation according to any one of claims 1 to 9, comprising 5 to 30% by weight plasticizer.

11. The chewable formulation according to any one of claims 1 to 10, comprising one or more humectants.

12. The le formulation according to claim 11, comprising 0.2 to 5% by weight humectant.

13. The chewable formulation according to claim 11 or 12, wherein the humectant is selected from propylene glycol and glycerine.

14. The chewable formulation according to any one of claims 1 to 13, comprising 2 to 18% by weight lubricant.

15. The le formulation ing to any one of claims 1 to 14, comprising one or more egrating agents.

16. The chewable formulation according to claim 15, comprising to 15% by weight disintegrating agent.

17. The chewable formulation according to any one of claims 1 to 16, comprising 2 to 18% by weight fats, lipids or fats and .

18. The chewable formulation according to any one of claims 1 to 17, wherein the chewable ations provides at least 12 to 30 months shelf life.

19. The chewable ation according to any one of claims 1 to 18, wherein the chewable formulation delivers at least 80% of the active ingredient g within 50 to 95 minutes of administration to the target animal.

20. A method of manufacturing a shelf stable chewable veterinary formulation comprising mixing a nutritional ingredient or an effective amount of a pharmaceutically active agent with (1) a fat, lipid, or fat and lipid, wherein the fat, lipid, or fat and lipid is a lubricant, and (2) a filler, sweetener, or a filler and sweetener, to obtain a first composition, adding one or more plasticizers to the first mixture to obtain a second composition, extruding the second composition at a temperature sufficient to melt the fat, lipid, or fat and lipid, allowing the extruded second composition to cool to room temperature y providing the chewable formulation, and wherein the method of manufacture does not include the on of water.

21. The method according to claim 20, wherein the nutritional ingredient or pharmaceutically active agent is added by dry blending.

22. The method according to claim 20, wherein the nutritional ingredient or pharmaceutically active agent is ved in an appropriate solvent before addition.

23. The method according to claim 20, wherein the nutritional ingredient or pharmaceutically active agent is granulated before addition.

24. The method according to claim 20, wherein the nutritional ingredient or pharmaceutically active agent, optionally in granular form, are coated, or further coated, with a suitable coating.

25. The method according to claim 24, wherein the suitable coating is a coating polymer selected from polyethylene glycols, a wax, or a fatty acid.

26. The method according to claim 25, n the coating polymer is a saturated C18- C22 fatty acid.

27. The method according to claim 20, wherein the ional ingredient or an effective amount of a pharmaceutically active agent (optionally in ar form) are conjugated with other substances, such as cyclodextrins.

28. The method according to any one of claims 20 to 27, wherein the active ient is first combined with  a filler,  a diluent,  a sweetener,  a flavouring agent,  a binder,  a disintegrating agent, or  any combination of two or more of the above.

29. The method according to any one of claims 20 to 28, wherein each of the filler, t, sweetener, flavouring agent, binder and disintegrating agent are in dry state.

30. The method according to any one of claims 20 to 29, wherein the fat, lipid, or fat and lipid are ised before being added.

31. The method according to any one of claims 20 to 30, wherein one or more plasticisers are added to the second composition.

32. The method according to any one of claims 20 to 31, wherein the ion is performed under pressure sufficient to bind the ingredients together. Nutritional ingredient, or Pharmaceutically active agent Optionally  a filler, diluent or filler and diluent,  a binder,  a sweetener,  a flavouring agent,  a plasticizer, 2  a humectant,  a fat, lipid or fat and lipid,  an antioxidant,  a colouring agent, Pre-comp osition  a disintegrating agent,  a preservative, buffering agent, or preservative and buffering agent, 3  a lubricant, fat, lipid or fat and  a complexing agent,  a coating agent, lipid  a surfactant,  a solubility er, bioavailability enhancer, or a solubility enhancer and a bioavailability enhancer,  a bility er, or First composition  a ueous solvent or vehicle, 5  any combination of any two or more thereof. Optional plasticizer 4 Second composition Extrusion 8 Chewable formulation